Split (3)

train · 29.5k rows

FEATURE_phases list	FEATURE_enrollmentCount int64	FEATURE_allocation string	FEATURE_interventionModel string	FEATURE_primaryPurpose class label	FEATURE_masking class label	FEATURE_healthyVolunteers bool	FEATURE_sex class label	FEATURE_oversightHasDmc bool	FEATURE_briefSummary string	FEATURE_detailedDescription string	FEATURE_conditions string	FEATURE_conditionsKeywords string	FEATURE_protocolPdfText string	FEATURE_numArms int64	FEATURE_armDescriptions string	FEATURE_armGroupTypes list	FEATURE_numInterventions int64	FEATURE_interventionTypes list	FEATURE_interventionDescriptions string	FEATURE_interventionNames string	FEATURE_numLocations int64	FEATURE_locationDetails string	LABEL_ct_level_ade_population int64	LABEL_sum_dosing_errors int64	LABEL_dosing_error_rate float32	LABEL_wilson_label int64	METADATA_nctId string	METADATA_overallStatus class label	METADATA_completionDate date32	METADATA_startDate date32	METADATA_leadSponsorName string	METADATA_leadSponsorClass class label	METADATA_hasProtocol bool	METADATA_hasSap bool	METADATA_hasIcf bool	METADATA_protocolPdfLinks string	METADATA_count_Accidental overdose int64	METADATA_count_Incorrect dose administered int64	METADATA_count_Intentional overdose int64	METADATA_count_Multiple drug overdose int64	METADATA_count_Overdose int64	METADATA_wilson_lower_bound float32
[ 3 ]	32	NA	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	false	The goals of the project is to evaluate the effects of Heliox therapy on obstructive sleep apnea syndrome (OSAS).	Obstructive sleep apnea syndrome (OSAS) is a common condition affecting up to 2-4 % of the general population. The pathophysiologic consequences of OSA include: excessive daytime sleepiness leading to increased car and work related accidents; and increased incidence of hypertension (HTN), stroke and possibly coronary a...	Obstructive Sleep Apnea Syndrome	Heliox Obstructive Sleep Apnea	null	1	arm 1: Heliox which is a mix of oxygen and helium gase will be administered through a face mask during part of the sleep study.	[ 0 ]	1	[ 0 ]	intervention 1: From the onset of sleep until 2:00 am, patients will be placed on heliox 70/30. At 2:00 am patients will be switched to CPAP for titration according to American Academy of Sleep Medicine (AASM) guidelines.	intervention 1: Heliox	1	Staten Island \| New York \| United States \| -74.13986 \| 40.56233	32	0	0	0	NCT02135900	1COMPLETED	2011-04-01	2009-12-01	Northwell Health	7OTHER	false	false	false	null	0	0	0	0	0	0
[ 0 ]	80	RANDOMIZED	PARALLEL	0TREATMENT	2DOUBLE	false	0ALL	false	The post-thoracotomy pain (PTP) has been defined as persistent or recurrent pain that lasts for at least 2 month after thoracotomy and is associated with surgical incision or its intercostal nerve cutaneous distribution. The latter has a prevalence of about 15% to 20%. In about 80% of the patients such pain is moderate...	null	Perioperative Chest Pain		null	2	arm 1: 1\) Group I: Patients will receive topical 5% lidocaine patches. Those will be placed to affected area up to three patches as needed for pain 12 hours on and 12 hours off. They will also receive opioids as needed after the surgery. Initially, they may receive IV fentanyl repeated clinician boluses, later oxycodo...	[ 0, 2 ]	2	[ 0, 0 ]	intervention 1: Patients will receive Lidoderm topical 5% lidocaine patches. Those will be placed to affected area up to three patches as needed for pain 12 hours on and 12 hours off intervention 2: 2\) Group II: Patients will receive placebo patches. Those will be placed to affected area at dose up to three patches as...	intervention 1: Lidoderm 5 % Topical Patch intervention 2: Placebo patch	1	Cleveland \| Ohio \| United States \| -81.69541 \| 41.4995	78	0	0	0	NCT03120351	1COMPLETED	2011-04-01	2009-09-01	The Cleveland Clinic	7OTHER	false	false	false	null	0	0	0	0	0	0
[ 2 ]	28	RANDOMIZED	SEQUENTIAL	0TREATMENT	3TRIPLE	false	0ALL	false	The purpose of this study is to characterize the safety and tolerability of single rising doses of etelcalcetide in hemodialysis patients with secondary hyperparathyroidism.	null	Hyperparathyroidism, Secondary	Clinical Trial, Phase 1 Renal Dialysis Secondary Hyperparathyroidism Parathyroid hormone	null	2	arm 1: Participants received a single dose of placebo intravenous (IV) injection after hemodialysis. arm 2: Participants received a single dose of etelcalcetide by intravenous (IV) injection after hemodialysis.	[ 2, 0 ]	2	[ 0, 0 ]	intervention 1: Single IV injection. intervention 2: Single IV injection. The initial dose was 5 mg and dose escalation proceeded with subsequent doses of 10 mg, 20 mg, 40 mg and 60 mg.	intervention 1: Placebo intervention 2: Etelcalcetide	5	Cypress \| California \| United States \| -118.03729 \| 33.81696 Shreveport \| Louisiana \| United States \| -93.75018 \| 32.52515 Houston \| Texas \| United States \| -95.36327 \| 29.76328 Brisbane \| Queensland \| Australia \| 153.02809 \| -27.46794 Melbourne \| Victoria \| Australia \| 144.96332 \| -37.814	39	0	0	0	NCT01134562	1COMPLETED	2011-04-02	2010-09-07	KAI Pharmaceuticals	4INDUSTRY	false	false	false	null	0	0	0	0	0	0
[ 2 ]	35	RANDOMIZED	PARALLEL	0TREATMENT	0NONE	false	0ALL	false	This study will investigate the safety, side effects and how well the body tolerates MK-5108 as well as determine different doses of MK-5108 in participants with advanced and/or refractory solid tumors. The corresponding primary hypotheses of this study are that 1) administration of oral MK-5108 (twice daily for 2 out ...	null	Cancer, Neoplasms, Tumors		null	11	arm 1: Participants receive 200 mg of MK-5108 orally twice daily (BID) the first 2 days of a 14-day cycle (cycle extended to 21 days if ≥Grade 2 toxicity observed). arm 2: Participants receive 400 mg of MK-5108 orally BID the first 2 days of a 14-day cycle (cycle extended to 21 days if ≥Grade 2 toxicity observed). arm ...	[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]	2	[ 0, 0 ]	intervention 1: MK-5108 will be administered orally, every 12 hours (Q12H) during the first 2 days of each cycle. Cycle length will be 14-21 days in Panel 1 and 21 days in Panel 2. intervention 2: Docetaxel will be administered intravenously (I.V.) at a dose of 60 mg/m\^2 Q12H during the first 2 days of each 21-day cyc...	intervention 1: MK-5108 intervention 2: docetaxel	0	null	39	0	0	0	NCT00543387	1COMPLETED	2011-04-04	2008-03-27	Merck Sharp & Dohme LLC	4INDUSTRY	false	false	false	null	0	0	0	0	0	0
[ 3 ]	211	NA	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	null	This is an extension study for subjects who participated in Protocol 20090061 (NCT00950989). All subjects in this study will receive a 210mg injection of AMG827 for treatment for their Rheumatoid Arthritis for up to 5 years.	null	Rheumatoid Arthritis	Amgen RA AMG 827 20090061	null	4	arm 1: Participants who were administered matching placebo in parent study 20090061 and were administered 210 mg subcutaneous (SC) AMG 827 at Day 1, Week 1, Week 2, and every other week thereafter (Q2WK). Participants also continued to receive weekly intramuscular, oral or SC doses of methotrexate and folic acid or fol...	[ 0, 0, 0, 0 ]	1	[ 0 ]	intervention 1: AMG 827 210 mg	intervention 1: AMG 827	44	Scottsdale \| Arizona \| United States \| -111.89903 \| 33.50921 Tucson \| Arizona \| United States \| -110.92648 \| 32.22174 La Jolla \| California \| United States \| -117.2742 \| 32.84727 Victorville \| California \| United States \| -117.29116 \| 34.53611 Sarasota \| Florida \| United States \| -82.53065 \| 27.33643 Rock Island \| Illi...	211	0	0	0	NCT01059448	6TERMINATED	2011-04-05	2010-06-03	Amgen	4INDUSTRY	false	false	false	null	0	0	0	0	0	-0
[ 4 ]	31	NA	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	false	Our laboratory is studying a skin disease known as psoriasis. The purpose of this protocol is to study the action and the effects of Efalizumab, on psoriasis. This medication has been studied extensively and has been found to be effective and safe in the treatment of psoriasis. The eligible patient will have 10% of his...	The eligible patient will receive the drug Efalizumab, weekly for 12 weeks, by injection. The patient will be seen weekly for 12 weeks and every other week for the 12 weeks of follow up. At those visits, the patient can expect that a physical and skin exam will be done. At specific weeks, blood work will be drawn, clin...	Psoriasis	skin psoriasis	null	1	arm 1: moderate to severe plaque psoriasis	[ 0 ]	1	[ 0 ]	intervention 1: 24 weekly doses of 1.0 mg/kg Efalizumab. Study drug will be administered by SC injection	intervention 1: Efalizumab	2	New York \| New York \| United States \| -74.00597 \| 40.71427 New York \| New York \| United States \| -74.00597 \| 40.71427	30	0	0	0	NCT00115076	1COMPLETED	2011-04-06	2003-08-04	Rockefeller University	7OTHER	false	false	false	null	0	0	0	0	0	0
[ 3 ]	25	NA	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	null	Primary Objective: Evaluate the clinical activity of the RT-PEPC combination regimen (rituximab, thalidomide, and prednisone, etoposide, procarbazine, cyclophosphamide) in patients with relapsed mantle cell lymphoma. Specifically, response rate (RR) and time to disease progression (TTP) will be assessed. Secondary Ob...	null	Non-Hodgkin's Lymphoma	relapsed mantle cell lymphoma	null	1	arm 1: None	[ 0 ]	3	[ 0, 0, 0 ]	intervention 1: Induction phase (month 1-3) • PEPC daily (prednisone 20 mg/day, cyclophosphamide 50 mg/day, etoposide 50 mg/day, and procarbazine 50 mg/day) until expected drop in neutrophil count (ANC \< 3000), unless due to disease. After ANC returns to above 2,000/ul, PEPC resumes at alternate day or fractionated w...	intervention 1: PEPC intervention 2: Thalidomide intervention 3: Rituximab	1	New York \| New York \| United States \| -74.00597 \| 40.71427	22	0	0	0	NCT00151281	1COMPLETED	2011-04-07	2004-11-01	Weill Medical College of Cornell University	7OTHER	false	false	false	null	0	0	0	0	0	0
[ 3 ]	119	RANDOMIZED	PARALLEL	0TREATMENT	3TRIPLE	false	0ALL	false	Stage 1 is a patient-masked, dose-escalation, safety evaluation of brimonidine intravitreal implant. Patients will receive implant in one eye and "sham" treatment (meaning no treatment) in the fellow eye. Stage 2 will begin after 1 month of safety has been evaluated for Stage 1. Stage 2 is a randomized, double-masked, ...	null	Macular Degeneration		null	5	arm 1: Stage 1: 400 µg brimonidine tartrate implant in the study eye and sham in the fellow eye on Day 1 and Month 6. arm 2: Stage 1: 200 µg brimonidine tartrate implant in the study eye and sham in the fellow eye on Day 1 and Month 6. arm 3: Stage 2: 400 µg brimonidine tartrate implant in the study eye and sham in the...	[ 5, 5, 5, 5, 3 ]	3	[ 0, 0, 10 ]	intervention 1: 400 µg brimonidine tartrate implant in the study eye on Day 1 and Month 6. intervention 2: 200 µg brimonidine tartrate implant in the study eye on Day 1 and Month 6. intervention 3: Sham in one or both eyes on Day 1 and Month 6.	intervention 1: 400 µg Brimonidine Tartrate Implant intervention 2: 200 µg Brimonidine Tartrate Implant intervention 3: Sham (no implant)	7	Abilene \| Texas \| United States \| -99.73314 \| 32.44874 Sydney \| New South Wales \| Australia \| 151.20732 \| -33.86785 Karlsruhe \| N/A \| Germany \| 8.40444 \| 49.00937 Udine \| N/A \| Italy \| 13.23715 \| 46.0693 Makati City \| N/A \| Philippines \| 121.03269 \| 14.55027 Coimbra \| N/A \| Portugal \| -8.41955 \| 40.20564 Seoul \| N/A \| ...	117	0	0	0	NCT00658619	1COMPLETED	2011-04-08	2008-05-01	Allergan	4INDUSTRY	false	false	false	null	0	0	0	0	0	0
[ 3, 4 ]	4,548	RANDOMIZED	PARALLEL	0TREATMENT	3TRIPLE	false	1FEMALE	true	This is a multicenter study to test the hypothesis that telcagepant is superior to placebo in preventing perimenstrual migraines as measured by mean monthly headaches during the entire treatment period. This study will also evaluate the safety and tolerability of telcagepant for female migraine participants.	null	Migraine	Menstrually related migraine migraine Premenstrual migraine	null	2	arm 1: Telcagepant 140 mg was administered once daily at bedtime for 7 consecutive days each month, beginning at the onset of menses, for up to 6 months. Dosing could begin up to 3 days prior to menses onset if prodromal symptoms reliably predicted onset of menses. arm 2: Placebo was administered once daily at bedtime ...	[ 0, 2 ]	2	[ 0, 0 ]	intervention 1: Telcagepant 140 mg film coated tablet for oral administration intervention 2: Placebo to match telcagepant 140 mg film coated tablet for oral administration	intervention 1: Telcagepant intervention 2: Placebo	0	null	3,986	0	0	0	NCT01125774	1COMPLETED	2011-04-08	2010-06-01	Merck Sharp & Dohme LLC	4INDUSTRY	false	false	false	null	0	0	0	0	0	0
[ 2 ]	68	NA	SINGLE_GROUP	2DIAGNOSTIC	0NONE	false	0ALL	false	This study will use imaging to look at tumor response to combination chemotherapy of gemcitabine (Gem) and cisplatin (Cis) or gemcitabine and carboplatin (Carbo) in non small cell lung cancer (NSCLC).	null	Carcinoma Non-small Cell Lung Cancer		null	1	arm 1: None	[ 0 ]	2	[ 4, 0 ]	intervention 1: Participants have 4 computed tomography (CT) or magnetic resonance imaging (MRI) scans at screening, baseline, at the end of each treatment cycle (day 21 and day 42.) They also have FDG-PET scans, 2 at Baseline and one at the end of each treatment cycle. intervention 2: Gemcitabine administered intraven...	intervention 1: Comparator: CT or MRI and FDG-PET intervention 2: Gemcitabine and Cisplatin or Gemcitabine and Carboplatin	0	null	68	0	0	0	NCT00599755	1COMPLETED	2011-04-13	2009-01-01	Merck Sharp & Dohme LLC	4INDUSTRY	false	false	false	null	0	0	0	0	0	0
[ 4 ]	1,031	RANDOMIZED	PARALLEL	0TREATMENT	2DOUBLE	false	0ALL	false	The Purpose of this study is to assess the efficacy and safety of two strengths of the FF/GW642444 Inhalation Powder in subjects with chronic obstructive pulmonary disease (COPD)	null	Pulmonary Disease, Chronic Obstructive	Safety Chronic Obstructive Pulmonary Disease Efficacy FEV1 COPD	null	5	arm 1: Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA) arm 2: Inhaled Corticosteroid (ICS) arm 3: Long Acting Beta Agonist(LABA) arm 4: Placebo arm 5: Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA)	[ 0, 0, 0, 2, 0 ]	4	[ 0, 0, 0, 0 ]	intervention 1: Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA) for COPD intervention 2: Inhaled Corticosteroid (ICS) intervention 3: Long Acting Beta Agonist(LABA) intervention 4: Placebo	intervention 1: FF/GW642444 Inhalation Powder intervention 2: FF Inhalation Powder intervention 3: GW642444 Inhalation Powder intervention 4: Placebo	132	Mobile \| Alabama \| United States \| -88.04305 \| 30.69436 Montgomery \| Alabama \| United States \| -86.29997 \| 32.36681 Phoenix \| Arizona \| United States \| -112.07404 \| 33.44838 Scottsdale \| Arizona \| United States \| -111.89903 \| 33.50921 Encinitas \| California \| United States \| -117.29198 \| 33.03699 Rancho Mirage \| Califo...	1,030	0	0	0	NCT01053988	1COMPLETED	2011-04-14	2009-10-05	GlaxoSmithKline	4INDUSTRY	false	false	false	null	0	0	0	0	0	0
[ 3 ]	25	RANDOMIZED	CROSSOVER	0TREATMENT	2DOUBLE	false	0ALL	false	This study is a randomised, double-blind, placebo-controlled study to assess the efficacy of GW870086X cream formulation in subjects with moderate to severe atopic dermatitis. Subjects will be assigned to take 3 out of the 4 possible treatments for 21 ±2 days: GW870086X 0.2% cream, GW870086X 2% cream, FP 0.05% cream (a...	This study is a randomised, double-blind, placebo-controlled study to assess the efficacy of GW870086X cream formulation in subjects with moderate to severe atopic dermatitis. The primary objective of this study is to assess 3 lesions using the Three Item Severity (TIS) score. The secondary objectives are to assess saf...	Dermatitis, Atopic	Atopic Dermatitis GW870086X TIS IGA	null	3	arm 1: GW870086 2.0%, GW870086 0.2% \& Placebo each applied to a separate specific lesion for 21±2 days. arm 2: GW870086 2.0%, FP 0.05% \& Placebo each applied to a separate specific lesion for 21±2 days. arm 3: GW870086 0.2%, FP 0.05% \& Placebo each applied to a separate specific lesion for 21±2 days.	[ 0, 0, 0 ]	4	[ 0, 0, 0, 0 ]	intervention 1: White to slightly colored opaque cream intervention 2: White to slightly colored opaque cream intervention 3: White cream intervention 4: White to slightly colored opaque cream	intervention 1: GW870086 2.0% intervention 2: GW870086 0.2% intervention 3: FP 0.05% intervention 4: Placebo	1	Berlin \| N/A \| Germany \| 13.41053 \| 52.52437	25	0	0	0	NCT01299610	1COMPLETED	2011-04-14	2010-12-01	GlaxoSmithKline	4INDUSTRY	false	false	false	null	0	0	0	0	0	0
[ 3 ]	26	NA	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	true	The safety and efficacy of midostaurin (PKC412), a novel investigational drug, will be evaluated on the basis of response rate, when administered to patients with aggressive systemic mastocytosis (ASM) or mast cell leukemia (MCL)	This study assesses the activity and safety profile of twice-daily oral doses of midostaurin in patients with aggressive systemic mastocytosis (ASM) or mast cell leukemia (MCL) with or without associated clonal hematological non-mast cell lineage disease (AHNMD). Aggressive systemic mastocytosis (ASM) and mast cell le...	Systemic Mastocytosis, Aggressive (ASM) Leukemia, Mast Cell Hematological Non-mast Cell Lineage Disease (AHNMD)		null	1	arm 1: 100 mg midostaurin twice daily as oral capsules	[ 0 ]	1	[ 0 ]	intervention 1: Midostaurin is a broad-spectrum protein kinase inhibitor, acting on conventional PKC isoforms (α, β, γ); PDFRβ; VEGFR2; Syk; PKCη; Flk-1; Flt3; Cdk1/B; PKA; c-Kit; c-Fgr; c-Src; VEGFR1; and EGFR	intervention 1: Midostaurin	3	Stanford \| California \| United States \| -122.16608 \| 37.42411 Boston \| Massachusetts \| United States \| -71.05977 \| 42.35843 St Louis \| Missouri \| United States \| -90.19789 \| 38.62727	26	0	0	0	NCT00233454	1COMPLETED	2011-04-16	2005-03-01	Jason Robert Gotlib	7OTHER	false	false	false	null	0	0	0	0	0	0
[ 4 ]	674	NA	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	false	To provide long term safety data for rizatriptan in children and adolescents. The primary hypothesis of the study is that rizatriptan is well tolerated in the long term treatment of acute migraine in pediatric patients age 12-17 years.	null	Acute Migraine With or Without Aura in Adolescents	acute migraine with or without aura in adolescents	null	1	arm 1: Rizatriptan benzoate	[ 0 ]	1	[ 0 ]	intervention 1: Single dose of 5 mg or 10 mg orally disintegrating tablet at onset of migraine attack	intervention 1: rizatriptan benzoate	0	null	606	148	0.244224	1	NCT01004263	1COMPLETED	2011-04-18	2009-12-01	Organon and Co	4INDUSTRY	false	false	false	null	148	0	0	0	0	0.211699
[ 4 ]	58	NA	SINGLE_GROUP	0TREATMENT	0NONE	true	0ALL	true	When post-operative parenteral analgesia is discontinued, oral dosing with study medication may begin once the subject has developed a moderate level of pain as defined by a 100 mm VAS (pain intensity score greater than or equal to 40). This post marketing study was required by the FDA. Endo Pharmaceuticals Inc. no lo...	null	Postoperative Pain	Opioid tolerant Pediatric Pain Non malignant Malignant	null	1	arm 1: Open-Label, 2 part ascending-dose multicenter study	[ 0 ]	1	[ 0 ]	intervention 1: Open-label, 2 part, ascending dose, single and multiple dose q4-6 hrs up to 48 hrs	intervention 1: Oxymorphone IR	11	Little Rock \| Arkansas \| United States \| -92.28959 \| 34.74648 Stanford \| California \| United States \| -122.16608 \| 37.42411 Aurora \| Colorado \| United States \| -104.83192 \| 39.72943 Washington D.C. \| District of Columbia \| United States \| -77.03637 \| 38.89511 Tampa \| Florida \| United States \| -82.45843 \| 27.94752 India...	58	0	0	0	NCT00801398	1COMPLETED	2011-04-18	2009-02-17	Endo Pharmaceuticals	4INDUSTRY	false	false	false	null	0	0	0	0	0	0
[ 3 ]	143	RANDOMIZED	PARALLEL	0TREATMENT	3TRIPLE	false	0ALL	false	To evaluate the efficacy of SPD489 for the treatment of executive function impairments (EFI) when used as an adjunct to stable, standard therapy in the setting of partial or full remission from recurrent Major Depressive Disorder (MDD) as measured by the Global Executive Composite (GEC) T-score of the Behavioral Rating...	null	Major Depressive Disorder	Major Depressive Disorder	null	2	arm 1: SPD489 arm 2: Placebo	[ 0, 2 ]	2	[ 0, 0 ]	intervention 1: Oral, 20, 30, 40, 50, 60, and 70mg capsules, once daily intervention 2: oral, once daily	intervention 1: SPD489 (Lisdexamfetamine dimesylate) intervention 2: Matching placebo	33	Imperial \| California \| United States \| -115.56944 \| 32.84755 Los Alamitos \| California \| United States \| -118.07256 \| 33.80307 Oceanside \| California \| United States \| -117.37948 \| 33.19587 Santa Ana \| California \| United States \| -117.86783 \| 33.74557 Cromwell \| Connecticut \| United States \| -72.64537 \| 41.5951 Jacks...	143	0	0	0	NCT00985725	1COMPLETED	2011-04-18	2009-10-29	Shire	4INDUSTRY	false	false	false	null	0	0	0	0	0	0
[ 3 ]	40	RANDOMIZED	CROSSOVER	0TREATMENT	2DOUBLE	false	0ALL	false	The purpose of this study is to assess the pharmacodynamic (PD) effects (Total Symptom Score (TSS) and its individual components: rhinorrhoea, nasal congestion, post-nasal drip) of intranasal, repeat dose SB-705498 in non-allergic rhinitis (NAR) patients elicited by a cold dry air challenge in an environmental exposure...	null	Rhinitis		null	2	arm 1: None arm 2: None	[ 0, 2 ]	2	[ 0, 0 ]	intervention 1: 12mg intra nasal intervention 2: Placebo intra nasal	intervention 1: SB-705498 intervention 2: Placebo	1	Mississauga \| Ontario \| Canada \| -79.6583 \| 43.5789	77	0	0	0	NCT01424514	1COMPLETED	2011-04-18	2010-12-01	GlaxoSmithKline	4INDUSTRY	false	false	false	null	0	0	0	0	0	-0
[ 5 ]	44	RANDOMIZED	PARALLEL	1PREVENTION	0NONE	false	0ALL	false	Transplant recipients have a high risk to develop skin malignancies. This effect depends on the one hand on the immunosuppressive drugs themselves (i.e., azathioprine) and relates on the other hand on the dosage (i.e., calcineurin-inhibitors). Based on the encouraging results of previous, retrospective studies on patie...	Patients who meet all inclusion criteria will be included into the study and randomised. If converted to SRL, patients will take SRL according to the investigator's instructions and medication label, once daily preferably 4 hours after calcineurin-inhibitor medication or in case without calcineurin-inhibitor co-medicat...	Skin Cancer	Renal transplant-patients with high-risk for skin cancer	null	2	arm 1: Patients will receive Sirolimus in addition to their previous immunosuppressive therapy. arm 2: Patients will stay on their previous immunosuppressive regimen.	[ 0, 1 ]	5	[ 0, 0, 0, 0, 0 ]	intervention 1: Treatment arm Dosage: 4-8 micrograms/litre; Route of administration: oral use; Frequency: one tablet per day intervention 2: control arm Dosage form: Coated tablet; dosage: 1-4 milligrams/kilogram; Frequency: daily; Duration: 24 month intervention 3: Control arm Dosage form: Tablet; dosage: 2 gram; Freq...	intervention 1: Sirolimus intervention 2: Azathioprine intervention 3: Mycophenolate intervention 4: Ciclosporin intervention 5: Tacrolimus	15	Erlangen \| Bavaria \| Germany \| 11.00783 \| 49.59099 Erlangen \| Bavaria \| Germany \| 11.00783 \| 49.59099 München \| Bavaria \| Germany \| 13.46314 \| 48.69668 München \| Bavaria \| Germany \| 13.46314 \| 48.69668 München \| Bavaria \| Germany \| 13.46314 \| 48.69668 München \| Bavaria \| Germany \| 13.46314 \| 48.69668 Regensburg \| Bavar...	44	0	0	0	NCT00866684	6TERMINATED	2011-04-19	2007-01-01	Charite University, Berlin, Germany	7OTHER	false	false	false	null	0	0	0	0	0	0
[ 2, 3 ]	40	NA	SINGLE_GROUP	2DIAGNOSTIC	0NONE	false	2MALE	false	Background: * Prostate cancers are difficult to see on most imaging studies such as X-rays, computed tomography (CT) scans, conventional magnetic resonance imaging (MRI) scans and conventional positron emission tomography (PET) scans. * An experimental radioactive tracer called 11C-acetate accumulates in prostate tumo...	Background: * Accurate localization of prostate cancer (PC) is important in developing targeted minimally invasive therapies. While T2 weighted imaging, dynamic contrast enhanced (DCE) imaging, diffusion weighted imaging (DWI), and magnetic resonance (MR) spectroscopy imaging performed at 3T is a useful technique for ...	Prostate Cancer	Prostate Cancer MRI C-11 Acetate PET	null	1	arm 1: 11C-acetate positron emission tomography (PET)/computed tomography (CT)for 30 minutes, intravenous bolus injection	[ 0 ]	1	[ 0 ]	intervention 1: 11C-acetate positron emission tomography (PET)/computed tomography (CT)for 30 minutes, intravenous bolus injection	intervention 1: (C-11 Acetate)	1	Bethesda \| Maryland \| United States \| -77.10026 \| 38.98067	40	0	0	0	NCT00924313	1COMPLETED	2011-04-19	2008-09-10	National Cancer Institute (NCI)	0NIH	false	false	false	null	0	0	0	0	0	0
[ 4 ]	1,886	RANDOMIZED	PARALLEL	0TREATMENT	0NONE	false	0ALL	null	This 2 arm study will compare the efficacy and safety of intermittent oral Xeloda plus Eloxatin (oxaliplatin) with that of fluorouracil/leucovorin in patients who have had surgery for colon cancer and no previous chemotherapy. Patients will be randomized to receive either 1) XELOX (Xeloda 1000mg/m2 po bid on days 1-15 ...	null	Colorectal Cancer		null	2	arm 1: Participants were given one of two regimens (each participating center prespecified which regimen they would use for all patients at that center): i) Mayo Clinic regimen group: LV 20 mg/m\^2 IV bolus injection + 5-FU 425 mg/m\^2 IV bolus injection daily on Days 1-5 of a four-week cycle, for a total of six cycles...	[ 1, 0 ]	4	[ 0, 0, 0, 0 ]	intervention 1: 1000 milligrams per square metre of body surface area (mg/m\^2) orally twice daily on days 1-15 of each 3-week cycle. intervention 2: 130 mg/m\^2 intravenous (IV) infusion over two hours on Day 1 of each 3-week cycle. intervention 3: Administered by one of two regimens, as specified in the arm descripti...	intervention 1: Capecitabine intervention 2: Oxaliplatin intervention 3: Leucovorin (LV) intervention 4: 5-Fluorouracil (5-FU)	232	Mobile \| Alabama \| United States \| -88.04305 \| 30.69436 Alhambra \| California \| United States \| -118.12701 \| 34.09529 Bakersfield \| California \| United States \| -119.01871 \| 35.37329 Fullerton \| California \| United States \| -117.92534 \| 33.87029 Long Beach \| California \| United States \| -118.18923 \| 33.76696 Northridge...	1,864	1	0.000536	0	NCT00069121	1COMPLETED	2011-04-21	2003-04-18	Hoffmann-La Roche	4INDUSTRY	false	false	false	null	1	0	0	0	0	0.000095
[ 4 ]	1,382	RANDOMIZED	PARALLEL	0TREATMENT	3TRIPLE	false	0ALL	true	This Clinical Trial evaluates the Safety and Efficacy of Rizatriptan for the Acute Treatment of Migraine in Children and Adolescents.	null	Migraine, Acute		null	4	arm 1: None arm 2: None arm 3: None arm 4: None	[ 0, 2, 0, 2 ]	4	[ 0, 0, 0, 0 ]	intervention 1: For participants randomized to rizatriptan in Stage 1: a single 5 or 10 mg rizatriptan orally disintegrating tablet (ODT) was to be taken within 30 minutes of onset of qualifying migraine (defined as a migraine of moderate or severe intensity). Rizatriptan dose administered was based on participant wei...	intervention 1: rizatriptan intervention 2: placebo intervention 3: rizatriptan intervention 4: placebo	0	null	977	0	0	0	NCT01001234	1COMPLETED	2011-04-21	2009-11-30	Organon and Co	4INDUSTRY	false	false	false	null	0	0	0	0	0	0
[ 3 ]	153	RANDOMIZED	PARALLEL	0TREATMENT	0NONE	false	0ALL	null	The addition of chemotherapy to radiotherapy (chemoradiation) has improved outcomes for patients with locally advanced squamous cell carcinoma of the head and neck but additional improvements to treatment regimens are needed. The study is investigating if the addition of a targeted therapy (panitumumab) can improve the...	null	Head and Neck Cancer Squamous Cell Carcinoma	Head and Neck Cancer panitumumab	null	2	arm 1: Participants received standard radiation therapy for 7 weeks and cisplatin 75 mg/m\^2 and panitumumab 9 mg/kg on Days 1, 22 and 43. arm 2: Participants received standard radiation therapy for 7 weeks and cisplatin 100 mg/m\^2 on Days 1, 22, and 43.	[ 0, 1 ]	3	[ 0, 4, 0 ]	intervention 1: Administered intravenously (IV; in a vein) intervention 2: 70 Gy administered in 2 Gy fractions daily for 5 days a week for 7 weeks (35 fractions) intervention 3: Administered intravenously	intervention 1: Cisplatin intervention 2: Standard Fractionation Radiotherapy intervention 3: Panitumumab	0	null	150	0	0	0	NCT00500760	1COMPLETED	2011-04-26	2007-10-01	Amgen	4INDUSTRY	false	false	false	null	0	0	0	0	0	0
[ 3 ]	14	NA	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	true	This study tests the hypothesis that a purely immunosuppressive preparative regimen allows engraftment of related or unrelated allogeneic hematopoietic stem cells in subjects with high-risk malignancies, without causing the post-transplant myelosuppression (e.g., neutropenia, thrombocytopenia) that occurs with currentl...	Primary Objectives of the study: * To determine the efficacy of a preparative regimen of pentostatin and alemtuzumab plus related or unrelated allogeneic peripheral blood stem cell transplantation (PBSCT) in inducing durable donor lymphohematopoietic cell chimerism (defined as at least 50% donor cells in the periphera...	Leukemia Lymphoma Hodgkin's Disease Hematologic Neoplasms Multiple Myeloma Carcinoma, Renal Cell	Allogeneic Hematopoietic Cell Transplantation Preparative Regimen Pentostatin Alemtuzumab Hodgkin Disease and Lymphoma, non-Hodgkin leukemia, myeloid, acute leukemia, lymphocytic, acute leukemia, myeloid, chronic leukemia, lymphocytic, chronic Multiple Myeloma Myelodysplastic Syndromes Carcinoma, Renal Cell	null	1	arm 1: Days - 8 through -6: pentostatin 4 mg/m2/24 hr as a continuous intravenous infusion (CIVI) (total cumulative dose, 12 mg/m2 over 3 days) Days - 5 through - 1: alemtuzumab 20 mg per dose intravenously over 8 hours daily for 5 doses (total cumulative dose, 100 mg) Followed by Allogeneic hematopoietic stem cell t...	[ 0 ]	3	[ 0, 2, 3 ]	intervention 1: Days - 8 through -6: pentostatin 4 mg/m2/24 hr as a continuous intravenous infusion (CIVI) (total cumulative dose, 12 mg/m2 over 3 days) intervention 2: Days - 5 through - 1: alemtuzumab 20 mg per dose intravenously over 8 hours daily for 5 doses (total cumulative dose, 100 mg) intervention 3: Infusion ...	intervention 1: Pentostatin intervention 2: Alemtuzumab intervention 3: Allogeneic hematopoietic stem cell transplantation	2	Tucson \| Arizona \| United States \| -110.92648 \| 32.22174 Tucson \| Arizona \| United States \| -110.92648 \| 32.22174	13	0	0	0	NCT00698685	6TERMINATED	2011-04-26	2006-01-23	University of Arizona	7OTHER	false	false	false	null	0	0	0	0	0	0
[ 4 ]	597	RANDOMIZED	PARALLEL	0TREATMENT	2DOUBLE	false	0ALL	false	This study will evaluate the safety and efficacy of bimatoprost 0.03% formulation B ophthalmic solution with LUMIGAN® (bimatoprost ophthalmic solution 0.03%) once daily for 12 weeks in patients with glaucoma or ocular hypertension	null	Glaucoma Ocular Hypertension		null	2	arm 1: Bimatoprost 0.03% Formulation B Ophthalmic Solution arm 2: Bimatoprost 0.03% Ophthalmic Solution	[ 0, 1 ]	2	[ 0, 0 ]	intervention 1: One drop administered in each eye, every evening, for 12 weeks intervention 2: One drop administered in each eye, every evening, for 12 weeks	intervention 1: Bimatoprost 0.03% Formulation B Ophthalmic Solution intervention 2: Bimatoprost 0.03% Ophthalmic Solution	1	Newport Beach \| California \| United States \| -117.92895 \| 33.61891	596	0	0	0	NCT01099774	1COMPLETED	2011-04-29	2010-05-01	Allergan	4INDUSTRY	false	false	false	null	0	0	0	0	0	0
[ 3 ]	110	NA	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	false	The purpose of this study is to evaluate the effects of cinacalcet on markers of bone turnover in patients with kidney disease who are receiving dialysis.	Secondary hyperparathyroidism (HPT) is common in people with end stage renal disease (kidney disease). Patients with secondary HPT often have enlarged parathyroid glands in the neck and as a result often have elevated parathyroid hormone (PTH) levels . Patients with secondary HPT may have bone disease (osteodystrophy)....	Secondary Hyperparathyroidism	Cinacalcet HCl, Cinacalcet, Amgen (AMG) 073, Sensipar, Mimpara, Calcimimetic	null	1	arm 1: All subjects were enrolled into the single arm to receive Cinacalcet. There was no comparator arm.	[ 0 ]	1	[ 0 ]	intervention 1: All enrolled subjects receive study medication at a starting dose of 30 mg cinacalcet once daily beginning on day 1. Possible sequential doses are 30 mg, 60mg, 90mg, 120mg, 180 mg taken once daily. During the study, dose adjustment (dose increase/decrease/withholding) is based upon iPTH, serum calcium, ...	intervention 1: Sensipar (Cinacalcet HCl)	55	Phoenix \| Arizona \| United States \| -112.07404 \| 33.44838 Los Angeles \| California \| United States \| -118.24368 \| 34.05223 Denver \| Colorado \| United States \| -104.9847 \| 39.73915 New Haven \| Connecticut \| United States \| -72.92816 \| 41.30815 Fort Lauderdale \| Florida \| United States \| -80.14338 \| 26.12231 Evanston \| I...	110	1	0.009091	1	NCT00261950	1COMPLETED	2011-05-01	2006-05-01	Amgen	4INDUSTRY	false	false	false	null	1	0	0	0	0	0.001607
[ 4 ]	766	RANDOMIZED	PARALLEL	0TREATMENT	2DOUBLE	false	0ALL	true	The primary purpose of this study is to evaluate the effectiveness and safety of ustekinumab (CNTO 1275) in the treatment of patients with moderate to severe plaque psoriasis.	This is a randomized (patients are assigned to different treatments based on chance), double blind (neither the patient nor the physician knows whether medication or placebo \[an inactive substance that is compared with a medication to test whether the medication has a real effect in a clinical study\] is being taken, ...	Psoriasis	Ustekinumab CNTO1275 Plaque type Psoriasis Interleukin-23 IL-23 Psoriasis Interleukin 12 IL-12	null	3	arm 1: Patients received ustekinumab 45 mg at Weeks 0, 4 and 16. Treatments after Week 16 were dependent on clinical response. At Week 40, patients who achieved PASI 75 at both Week 28 and Week 40 were re-randomized to withdraw from therapy (placebo) or continue 45 mg every 12 week maintenance therapy. arm 2: Patients ...	[ 0, 0, 2 ]	2	[ 0, 0 ]	intervention 1: Type = exact number, Form = solution for injection, Number = 45 and 90, Unit = mg, Route = subcutaneous (SC) administered at Weeks 0, 4 and 16. Both treatments (45 mg and 90 mg) administered every 12 weeks after Week 16 depending on clinical response. intervention 2: Form = solution for injection, route...	intervention 1: ustekinumab intervention 2: placebo	42	Phoenix \| Arizona \| United States \| -112.07404 \| 33.44838 Los Angeles \| California \| United States \| -118.24368 \| 34.05223 Redwood City \| California \| United States \| -122.23635 \| 37.48522 Santa Monica \| California \| United States \| -118.49138 \| 34.01949 Denver \| Colorado \| United States \| -104.9847 \| 39.73915 Wilmingt...	1,514	1	0.000661	1	NCT00267969	1COMPLETED	2011-05-01	2005-12-01	Centocor Research & Development, Inc.	4INDUSTRY	false	false	false	null	0	0	0	0	1	0.000117
[ 4 ]	351	RANDOMIZED	PARALLEL	0TREATMENT	2DOUBLE	false	0ALL	null	This study will investigate the safety and efficacy of raltegravir as a therapy for Human Immunodeficiency Virus (HIV)-infected patients failing current therapy with 3-class antiviral resistance.	The primary double-blind study of raltegravir versus placebo was extended to 156 weeks and was followed by an open-label raltegravir phase in which continuing participants from both the raltegravir and placebo groups received open-label raltegravir for an additional 84 weeks for a maximum duration of up to 240 weeks. P...	HIV Infections	Treatment Experienced	null	2	arm 1: raltegravir potassium arm 2: Placebo	[ 0, 2 ]	2	[ 0, 0 ]	intervention 1: Raltegravir 400 mg twice daily (b.i.d.) by mouth (p.o.) with optimized background therapy. Treatment period of 48 weeks. intervention 2: Placebo p.o. b.i.d. with optimized background therapy. Treatment period of 48 weeks.	intervention 1: raltegravir potassium intervention 2: Comparator: placebo	0	null	349	3	0.008596	1	NCT00293254	1COMPLETED	2011-05-01	2006-02-01	Merck Sharp & Dohme LLC	4INDUSTRY	false	false	false	null	1	0	1	0	1	0.002928
[ 4 ]	352	RANDOMIZED	PARALLEL	0TREATMENT	2DOUBLE	false	0ALL	true	This study will investigate the safety and efficacy of raltegravir as a therapy for HIV-infected patients failing current therapy with 3-class antiviral resistance.	The primary double-blind study of raltegravir versus placebo was extended to 156 weeks and was followed by an open-label raltegravir phase in which continuing participants from both the raltegravir and placebo groups received open-label raltegravir for an additional 84 weeks for a maximum duration of up to 240 weeks. P...	HIV Infections	Treatment Experienced	null	2	arm 1: raltegravir potassium arm 2: Placebo	[ 0, 2 ]	2	[ 0, 0 ]	intervention 1: Raltegravir 400 mg twice daily (b.i.d.) by mouth (p.o.) with optimized background therapy. Treatment period of 48 weeks. intervention 2: Placebo b.i.d. p.o. with optimized background therapy. Treatment period of 48 weeks.	intervention 1: raltegravir potassium intervention 2: Comparator: Placebo	0	null	350	5	0.014286	1	NCT00293267	1COMPLETED	2011-05-01	2006-02-01	Merck Sharp & Dohme LLC	4INDUSTRY	false	false	false	null	1	0	1	0	3	0.006117
[ 3 ]	217	NA	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	true	Subjects who qualify will receive oral lenalidomide daily on days 1-21 of every 28 day cycle. Treatment will continue until disease progression, or unacceptable adverse events develop	null	Lymphoma, Non-Hodgkin's	Celgene Revlimid CC-5013 Non-hodgkin's lymphoma Lenalidomide CC5013 NHL	null	1	arm 1: 25 mg oral lenalidomide once daily on Days 1-21 every 28 days	[ 0 ]	1	[ 0 ]	intervention 1: once daily oral capsule	intervention 1: lenalidomide	53	Muscle Shoals \| Alabama \| United States \| -87.66753 \| 34.74481 Scottsdale \| Arizona \| United States \| -111.89903 \| 33.50921 Fountain Valley \| California \| United States \| -117.95367 \| 33.70918 Rancho Mirage \| California \| United States \| -116.41279 \| 33.73974 San Diego \| California \| United States \| -117.16472 \| 32.715...	217	1	0.004608	1	NCT00413036	1COMPLETED	2011-05-01	2006-06-01	Celgene	4INDUSTRY	false	false	false	null	0	0	1	0	0	0.000814
[ 4 ]	6,758	RANDOMIZED	PARALLEL	1PREVENTION	2DOUBLE	false	0ALL	true	The purpose of this study is to learn if apixaban can prevent blood clots in the leg (deep vein thrombosis \[DVT\]) and lung (pulmonary embolism \[PE\]) that sometimes occur within patients hospitalized for acute medical illness, and to learn how apixaban compares to enoxaparin (Lovenox®) for preventing these clots. Th...	null	Venous Thrombosis Pulmonary Embolism	Prevention of deep vein thrombosis and pulmonary embolism with acutely ill hospitalized patients	null	2	arm 1: While hospitalized, Apixaban plus Placebo Apixaban (Tablets, Oral, 2.5 mg), Placebo (Syringes, SC) After hospital discharge, Apixaban Apixaban (Tablets, Oral, 2.5 mg) arm 2: While hospitalized, Enoxaparin plus Placebo Enoxaparin (Syringes, SC, 40 mg), Placebo (Tablets, Oral) After hospital discharge: Placeb...	[ 0, 1 ]	2	[ 0, 0 ]	intervention 1: Apixaban: Twice daily, 30 days Placebo: Once daily, 6-14 days intervention 2: Enoxaparin: Once daily, 6-14 days Placebo: Twice daily, 30 days	intervention 1: Apixaban intervention 2: Enoxaparin	296	Birmingham \| Alabama \| United States \| -86.80249 \| 33.52066 Huntsville \| Alabama \| United States \| -86.58594 \| 34.7304 Phoenix \| Arizona \| United States \| -112.07404 \| 33.44838 Scottsdale \| Arizona \| United States \| -111.89903 \| 33.50921 Fort Smith \| Arkansas \| United States \| -94.39855 \| 35.38592 La Jolla \| California...	6,401	3	0.000469	1	NCT00457002	1COMPLETED	2011-05-01	2007-06-01	Bristol-Myers Squibb	4INDUSTRY	false	false	false	null	0	0	0	0	3	0.000159
[ 4 ]	1,584	RANDOMIZED	PARALLEL	0TREATMENT	3TRIPLE	false	0ALL	null	The purpose of this study was to support the optimal use of rivastigmine patch in long-term treatment of Alzheimer's Disease in patients demonstrating functional and cognitive decline at the target maintenance dose of rivastigmine patch 10 cm\^2.	null	Alzheimer Disease	Alzheimer's Patch Cognitive Decline	null	4	arm 1: Rivastigmine 5 cm\^2 transdermal patch once a day during the first 4 weeks of open label treatment followed by rivastigmine 10 cm\^2 transdermal patch once a day from week 4 to week 24, 36 or 48. arm 2: Rivastigmine transdermal patch 10 cm\^2 and placebo to rivastigmine 15 cm\^2 once daily for 48 weeks during th...	[ 0, 0, 0, 0 ]	5	[ 0, 0, 0, 0, 0 ]	intervention 1: 5 cm\^2 transdermal patch intervention 2: 10 cm\^2 transdermal patch. intervention 3: 15 cm\^2 transdermal patch. intervention 4: Placebo of rivastigmine transdermal patch 15 cm\^2. intervention 5: Placebo of rivastigmine transdermal patch 10 cm\^2.	intervention 1: Rivastigmine 5 cm^2 intervention 2: Rivastigmine 10 cm^2 intervention 3: Rivastigmine 15 cm^2 intervention 4: Placebo to 15 cm^2 patch intervention 5: Placebo to 10 cm^2 patch	145	Birmingham \| Alabama \| United States \| -86.80249 \| 33.52066 Gilbert \| Arizona \| United States \| -111.78903 \| 33.35283 Phoenix \| Arizona \| United States \| -112.07404 \| 33.44838 Sun City \| Arizona \| United States \| -112.27182 \| 33.59754 Anaheim \| California \| United States \| -117.9145 \| 33.83529 Carson \| California \| Uni...	2,602	1	0.000384	0	NCT00506415	1COMPLETED	2011-05-01	2007-06-01	Novartis Pharmaceuticals	4INDUSTRY	false	false	false	null	1	0	0	0	0	0.000068
[ 3 ]	191	RANDOMIZED	PARALLEL	0TREATMENT	2DOUBLE	false	0ALL	false	The purpose of this study is to determine an optimal abatacept dosing regimen for the treatment of active arthritis due to psoriatic arthritis in patients who have had a prior inadequate response to disease-modifying antirheumatic drugs, including methotrexate and tumor necrosis factor alpha-blockade compounds.	null	Psoriatic Arthritis		null	4	arm 1: Abatacept (30 mg/kg) was administered as intravenous (iv) infusion over approximately 30 minutes on Days 1 and 15, followed by 10 mg/kg (fixed dose) abatacept infusion on Day 29 and every 28 days thereafter up to and including Day 141. The dose was calculated based on screening visit weight of participants for d...	[ 1, 1, 1, 2 ]	2	[ 0, 0 ]	intervention 1: Solution, intravenous, monthly, short-term = 24 weeks (6 months) intervention 2: Solution, intravenous, placebo (double dummy), monthly, short-term = 24 weeks (6 months)	intervention 1: Abatacept intervention 2: Placebo	44	Huntsville \| Alabama \| United States \| -86.58594 \| 34.7304 Palm Desert \| California \| United States \| -116.37697 \| 33.72255 Palo Alto \| California \| United States \| -122.14302 \| 37.44188 Upland \| California \| United States \| -117.64839 \| 34.09751 Bridgeport \| Connecticut \| United States \| -73.18945 \| 41.17923 Trumbull ...	317	1	0.003155	1	NCT00534313	6TERMINATED	2011-05-01	2007-11-01	Bristol-Myers Squibb	4INDUSTRY	false	false	false	null	0	0	0	0	1	0.000557
[ 5 ]	834	RANDOMIZED	PARALLEL	0TREATMENT	3TRIPLE	false	0ALL	false	To compare the efficacy of the combination of etanercept 50 mg once weekly plus methotrexate with that of methotrexate monotherapy in the treatment of rheumatoid arthritis over 88 weeks.	null	Arthritis, Rheumatoid	Active Rheumatoid Arthritis	null	3	arm 1: None arm 2: None arm 3: None	[ 1, 1, 2 ]	6	[ 0, 0, 0, 0, 0, 0 ]	intervention 1: Subcutaneous (SC), 50 mg, once weekly for 88 weeks intervention 2: Oral, 15 to 25 mg (varying based on dosage the subject is receiving at the time of screening and may be increased at the discretion of the investigator through Week 28 to a maximum of 25 mg/week), once weekly for 88 weeks. If a subject ...	intervention 1: Etanercept intervention 2: Methotrexate intervention 3: Etanercept intervention 4: Methotrexate intervention 5: Placebo intervention 6: Methotrexate	81	Campsie \| New South Wales \| Australia \| 151.10279 \| -33.9125 Kogarah \| New South Wales \| Australia \| 151.13564 \| -33.9681 Maroochydore \| Queensland \| Australia \| 153.09953 \| -26.66008 Daw Park \| South Australia \| Australia \| 138.58407 \| -34.98975 Heidelberg West \| Victoria \| Australia \| 145.04034 \| -37.73922 Malvern \| ...	1,438	2	0.001391	1	NCT00565409	1COMPLETED	2011-05-01	2008-03-01	Pfizer	4INDUSTRY	false	false	false	null	1	0	0	0	1	0.000381
[ 3 ]	79	RANDOMIZED	PARALLEL	0TREATMENT	0NONE	false	1FEMALE	false	The purpose of this study was to estimate the response rate of ixabepilone monotherapy, and the combination of ixabepilone plus cetuximab as first-line treatment of female subjects with triple negative (estrogen receptor \[ER\], progesterone receptor \[PR\], Human Epidermal Growth Factor Receptor 2 \[HER2\] negative) l...	null	Triple Negative Locally Advanced Non-resectable Breast Cancer Metastatic Breast Cancer		null	2	arm 1: ixabepilone 40 mg/m\^2 every 3 weeks arm 2: cetuximab 400 mg/m\^2 loading dose then 250 mg/m\^2 weekly + ixabepilone 40 mg/m\^2 every 3 weeks	[ 0, 0 ]	2	[ 0, 0 ]	intervention 1: injection, intravenous (IV), until unacceptable toxicity or progression or 15 months after the Last Subject First Visit (LSFV), whichever comes first. Ixabepilone 40 mg/m\^2 was administered as a 3-hour IV continuous infusion on Day 1 in a 21-day cycle provided the participant met the re-treatment crit...	intervention 1: ixabepilone intervention 2: ixabepilone + cetuximab	19	Graz \| N/A \| Austria \| 15.45 \| 47.06667 Vienna \| N/A \| Austria \| 16.37208 \| 48.20849 Brno \| N/A \| Czechia \| 16.60796 \| 49.19522 Prague \| N/A \| Czechia \| 14.42076 \| 50.08804 Prague \| N/A \| Czechia \| 14.42076 \| 50.08804 Bayonne \| N/A \| France \| -1.473 \| 43.49316 Dijon \| N/A \| France \| 5.01667 \| 47.31667 Lyon \| N/A \| Fran...	77	1	0.012987	1	NCT00633464	1COMPLETED	2011-05-01	2008-06-01	R-Pharm	4INDUSTRY	false	false	false	null	0	0	0	0	1	0.002296
[ 4 ]	2,589	RANDOMIZED	PARALLEL	0TREATMENT	2DOUBLE	false	0ALL	null	The general aim of this study is to determine the comparative safety and efficacy of dabigatran etexilate 150 mg bid administered orally and warfarin Pro re nata (As needed/PRN) to maintain an International Normalised Ratio (INR) of 2.0-3.0 for 6 month treatment of acute symptomatic VTE. The primary objective is to in...	null	Thromboembolism		null	2	arm 1: Patients will receive 1 capsule containing 150 mg dabigatran etexilate/matching placebo twice daily arm 2: Patients will receive tablets PRN warfarin/matching placebo to maintain a target INR of 2.0-3.0	[ 0, 1 ]	2	[ 0, 0 ]	intervention 1: PRN (to maintain a target INR of 2.0-3.0) intervention 2: 150mg bid	intervention 1: Warfarin intervention 2: Dabigatran etexilate	220	Little Rock \| Arkansas \| United States \| -92.28959 \| 34.74648 Clearwater \| Florida \| United States \| -82.8001 \| 27.96585 Normal \| Illinois \| United States \| -88.99063 \| 40.5142 Shreveport \| Louisiana \| United States \| -93.75018 \| 32.52515 Stony Brook \| New York \| United States \| -73.14094 \| 40.92565 Columbus \| Ohio \| U...	2,568	1	0.000389	0	NCT00680186	1COMPLETED	2011-05-01	2008-04-01	Boehringer Ingelheim	4INDUSTRY	false	false	false	null	0	0	0	0	1	0.000069
[ 4 ]	451	NA	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	null	This was a prospective, open-label, Phase III, multicenter, single-arm trial designed to assess the safety, pharmacokinetics, and pharmacodynamics of an alternative dosing rate of rituximab in previously untreated patients with diffuse large B-cell lymphoma (DLBCL) and follicular non-Hodgkin lymphoma (NHL).	null	Non-Hodgkin's Lymphoma	Follicular NHL NHL Large B-Cell NHL	null	1	arm 1: Patients received 6 or 8 21-day cycles of CHOP (cyclophosphamide, hydroxydaunorubicin \[doxorubicin\], Oncovin \[vincristine\], prednisone) or CVP (cyclophosphamide, vincristine, prednisone) in combination with rituximab 375 mg/m\^2 administered by intravenous (IV) infusion on Day 1 of each cycle.	[ 0 ]	4	[ 0, 0, 0, 0 ]	intervention 1: During Cycle 1 rituximab was administered at an initial rate of 50 mg/hour. In the absence of infusion toxicity during Cycle 1, the infusion rate was escalated by 50 mg/h increments every 30 minutes to a maximum rate of 400 mg/hour. In case of infusion-related reactions, the infusion was interrupted or ...	intervention 1: Rituximab intervention 2: CHOP (cyclophosphamide, hydroxydaunorubicin [doxorubicin], Oncovin [vincristine], prednisone) intervention 3: CVP (cyclophosphamide, vincristine, prednisone) intervention 4: Analgesic/antipyretic and antihistamine drugs	0	null	425	1	0.002353	1	NCT00719472	1COMPLETED	2011-05-01	2008-07-01	Genentech, Inc.	4INDUSTRY	false	false	false	null	1	0	0	0	0	0.000415
[ 4 ]	775	RANDOMIZED	PARALLEL	0TREATMENT	2DOUBLE	false	0ALL	true	A study to evaluate the safety, tolerability and efficacy of once daily Raltegravir compared to twice daily raltegravir when each is given in combination with TRUVADA™ in treatment-naïve human immunodeficiency virus (HIV)-infected patients.	Following the 96-week double-blind study period (MK0518-071)(NCT00745823), subjects may enroll in an extension study (MK0518-071-10)(NCT00745823). From weeks 96 to 120, subjects' treatment assignments will remain as in the base study. From week 120 to 240, all subjects will receive open-label raltegravir (800 mg, once...	HIV	HIV Infections Treatment Naïve	null	2	arm 1: None arm 2: None	[ 1, 0 ]	3	[ 0, 0, 0 ]	intervention 1: Raltegravir 400 mg tablet by mouth (PO) twice daily (b.i.d.) + two raltegravir placebo tablets + one tablet of TRUVADA™ once daily (q.d.) intervention 2: Raltegravir 800 mg tablet PO q.d. + two raltegravir placebo tablets + one tablet TRUVADA™ q.d. intervention 3: One tablet TRUVADA™ q.d. (fixed combina...	intervention 1: Comparator: Raltegravir 400 mg b.i.d. intervention 2: Experimental: Raltegravir 800 mg q.d. intervention 3: TRUVADA™	0	null	770	1	0.001299	1	NCT00745823	6TERMINATED	2011-05-01	2008-09-01	Merck Sharp & Dohme LLC	4INDUSTRY	false	false	false	null	0	0	0	1	0	0.000229
[ 4 ]	202	RANDOMIZED	PARALLEL	0TREATMENT	4QUADRUPLE	false	0ALL	null	A multinational, multicenter, double blind, placebo-controlled study evaluating the efficacy and safety of imatinib as an add-on therapy in the treatment of patients with severe pulmonary arterial hypertension (PAH).	null	Pulmonary Arterial Hypertension	Pulmonary arterial hypertension Imatinib 6MWD Borg scale Pulmonary hypertension	null	2	arm 1: Imatinib mesylate (QTI571) 200 mg once daily for two weeks, increased to 400 mg once daily if well tolerated. If 400 mg dose was not well tolerated, a down titration to 200 mg once daily was permitted. arm 2: Placebo to imatinib mesylate taken once daily. Participants receiving placebo were allowed to receive al...	[ 0, 2 ]	2	[ 0, 0 ]	intervention 1: Two or 4 imatinib mesylate (QTI571) 100 mg film coated tablets once daily. intervention 2: Placebo to imatinib 100 mg film coated tablets	intervention 1: imatinib mesylate intervention 2: Placebo	95	Birmingham \| Alabama \| United States \| -86.80249 \| 33.52066 Phoenix \| Arizona \| United States \| -112.07404 \| 33.44838 Los Angeles \| California \| United States \| -118.24368 \| 34.05223 San Francisco \| California \| United States \| -122.41942 \| 37.77493 Aurora \| Colorado \| United States \| -104.83192 \| 39.72943 Clearwater \|...	201	1	0.004975	1	NCT00902174	1COMPLETED	2011-05-01	2009-09-01	Novartis Pharmaceuticals	4INDUSTRY	false	false	false	null	1	0	0	0	0	0.000879
[ 2 ]	6	NON_RANDOMIZED	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	null	The purpose of this study is to determine the metabolism and elimination of carbon-14 labeled eribulin acetate (14C-eribulin) in patients with advanced solid tumors.	The study will be conducted in two phases, the initial Study phase to administer the radio-labeled 14C-eribulin and collection of PK samples, and the Extension Phase when the patients will continue to receive non-radio-labeled eribulin. In the initial Study phase, patients will receive a single 2 mg flat dose of 14C-er...	Advanced Solid Tumors	Advanced Solid Tumors Failure of Multiple Prior Chemotherapy Regimens	null	1	arm 1: None	[ 0 ]	1	[ 0 ]	intervention 1: Cycle 1 day 1: radio-labeled dose of 2 mg radioactive eribulin, followed by 1.4 mg/m\^2 of non-radio-labeled eribulin thereafter on days 1 and 8 every 21 days.	intervention 1: eribulin	1	Amsterdam \| N/A \| Netherlands \| 4.88969 \| 52.37403	6	1	0.166667	1	NCT00908908	1COMPLETED	2011-05-01	2009-03-01	Eisai Inc.	4INDUSTRY	false	false	false	null	1	0	0	0	0	0.030053
[ 4 ]	493	RANDOMIZED	PARALLEL	0TREATMENT	0NONE	false	0ALL	false	This trial is conducted in Europe and in the United States of America (USA). The aim of this trial is to investigate the efficacy and safety of NN1250 (insulin degludec) in subjects with type 1 diabetes.	null	Diabetes Diabetes Mellitus, Type 1		null	3	arm 1: None arm 2: None arm 3: None	[ 0, 0, 1 ]	3	[ 0, 0, 0 ]	intervention 1: Injected subcutaneously (under the skin) once daily intervention 2: Insulin glargine injected subcutaneously (under the skin) once daily intervention 3: At least three daily doses at meal-time	intervention 1: insulin degludec intervention 2: insulin glargine intervention 3: insulin aspart	82	Encino \| California \| United States \| -118.50119 \| 34.15917 Fresno \| California \| United States \| -119.77237 \| 36.74773 Huntington Beach \| California \| United States \| -117.99923 \| 33.6603 Long Beach \| California \| United States \| -118.18923 \| 33.76696 Redondo Beach \| California \| United States \| -118.38841 \| 33.84918 ...	490	1	0.002041	1	NCT01079234	1COMPLETED	2011-05-01	2010-03-01	Novo Nordisk A/S	4INDUSTRY	false	false	false	null	0	1	0	0	0	0.00036
[ 3 ]	39	NA	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	false	RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining chemotherapy, radiation therapy, and surgery may kill more tumor cells. E7296 was conducted to study neoadjuvant chemotherapy...	OBJECTIVES: Primary objective: To evaluate the tolerability and toxicity of neoadjuvant cisplatin plus paclitaxel and postoperative chemoradiation therapy with fluorouracil plus leucovorin calcium in patients with high-risk gastric cancer. Secondary objectives: To assess the pathologic response of gastric tumors to n...	Gastric Cancer	stage II gastric cancer stage III gastric cancer stage IV gastric cancer adenocarcinoma of the stomach	null	1	arm 1: Patients receive 3 courses of preoperative neoadjuvant chemotherapy given on day 1 every 21 days. Courses consist of an intravenous infusion of cisplatin and a 3 hour intravenous infusion of paclitaxel on day 1. Patients then undergo surgery for tumor removal on day 63, followed 4-6 weeks later by one course of ...	[ 0 ]	6	[ 0, 0, 0, 0, 3, 4 ]	intervention 1: Cisplatin was administered as part of the neoadjuvant regimen. It was given at a dose of 75 mg/m² via IV over approximately one hour, on day 1 of each cycle. Three cycles were given. intervention 2: Postoperative regimen 5-FU, along with Leucovorin, was given by IV bolus, with 5-FU given immediately aft...	intervention 1: cisplatin intervention 2: fluorouracil intervention 3: leucovorin calcium intervention 4: paclitaxel intervention 5: surgery intervention 6: radiation therapy	30	Denver \| Colorado \| United States \| -104.9847 \| 39.73915 Atlanta \| Georgia \| United States \| -84.38798 \| 33.749 Chicago \| Illinois \| United States \| -87.65005 \| 41.85003 Chicago \| Illinois \| United States \| -87.65005 \| 41.85003 Evanston \| Illinois \| United States \| -87.69006 \| 42.04114 Urbana \| Illinois \| United States...	45	0	0	0	NCT00003298	1COMPLETED	2011-05-01	1999-06-01	ECOG-ACRIN Cancer Research Group	5NETWORK	false	false	false	null	0	0	0	0	0	0
[ 3 ]	40	NA	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	false	RATIONALE: Current therapies for adults with primary malignant brain tumors that have not responded to standard therapy provide very limited benefit to the patient. The anti-cancer properties of Antineoplaston therapy suggest that it may prove beneficial in the treatment of adults with primary malignant brain tumors th...	OBJECTIVES: * To determine the efficacy of Antineoplaston therapy in patients with primary malignant brain tumors that have not responded to standard therapy, as measured by an objective response to therapy (complete response, partial response or stable disease). * To determine the safety and tolerance of Antineoplast...	Malignant Brain Tumors	adult glioblastoma multiforme adult anaplastic astrocytoma adult anaplastic astrocytoma/Mixed	null	1	arm 1: Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.	[ 0 ]	1	[ 0 ]	intervention 1: Adults with a primary malignant brain tumor that has not responded to standard therapy will receive Antineoplaston therapy (Atengenal + Astugenal). The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is im...	intervention 1: Antineoplaston therapy (Atengenal + Astugenal)	1	Houston \| Texas \| United States \| -95.36327 \| 29.76328	40	0	0	0	NCT00003475	1COMPLETED	2011-05-01	1996-02-01	Burzynski Research Institute	7OTHER	false	false	false	null	0	0	0	0	0	0
[ 3 ]	100	RANDOMIZED	PARALLEL	0TREATMENT	4QUADRUPLE	false	0ALL	true	This study will examine the safety and effectiveness of the medicine metformin to help overweight children control their food intake, weight, insulin, cholesterol, and triglyceride (blood fat) levels. Obesity and high insulin levels can lead to high blood pressure, diabetes, high cholesterol and triglyceride levels and...	The prevalence of overweight and obesity in children and adolescents in the United States has doubled during the past 20 years. Obesity is closely linked with development of insulin resistance and other mediators of unfavorable cardiovascular risk, such as hypertension and dyslipidemia. These obesity-related risk facto...	Hyperinsulinemia Obesity	Child Body Fat Food Intake Diabetes Mellitus Dyslipidemia Vitamin B12 Childhood Obesity	null	2	arm 1: Subjects receive metformin plus a weight loss program arm 2: Subjects receive placebo plus a weight loss program	[ 1, 2 ]	2	[ 0, 0 ]	intervention 1: Medication studied for ability to alter body weight and body composition. intervention 2: Control capsules for metformin	intervention 1: Metformin HCL intervention 2: Placebo	1	Bethesda \| Maryland \| United States \| -77.10026 \| 38.98067	100	0	0	0	NCT00005669	1COMPLETED	2011-05-01	2000-05-01	Jack Yanovski, M.D.	0NIH	false	false	false	null	0	0	0	0	0	0
[ 3 ]	25	NON_RANDOMIZED	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	true	RATIONALE: Imatinib mesylate and interferon alfa may interfere with the growth of the cancer cells. Combining imatinib mesylate with interferon alfa may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of combining imatinib mesylate with interferon alfa in treating patients who have chronic m...	OBJECTIVES: * Determine the maximum tolerated dose of interferon alfa administered with imatinib mesylate in patients with chronic phase chronic myelogenous leukemia. (Phase I closed to accrual as of 7/9/03.) * Determine the safety and tolerability of this regimen in this patient population. * Determine the complete, ...	Leukemia	relapsing chronic myelogenous leukemia chronic phase chronic myelogenous leukemia Philadelphia chromosome positive chronic myelogenous leukemia	null	0	null	null	2	[ 2, 0 ]	intervention 1: IFN-α will be given at a dose ranging up to 5 MIU daily via subcutaneous injection. intervention 2: Once daily oral administration of STI571 (imatinib mesylate) at a dose of 400 mg or 600mg for 12 months.	intervention 1: recombinant interferon alfa intervention 2: imatinib mesylate	2	Chicago \| Illinois \| United States \| -87.65005 \| 41.85003 Portland \| Oregon \| United States \| -122.67621 \| 45.52345	25	0	0	0	NCT00015847	6TERMINATED	2011-05-01	2001-04-01	OHSU Knight Cancer Institute	7OTHER	false	false	false	null	0	0	0	0	0	0
[ 4 ]	185	RANDOMIZED	PARALLEL	0TREATMENT	1SINGLE	false	0ALL	true	This randomized phase III trial studies aldesleukin with vaccine therapy to see how well it works compared to aldesleukin alone in treating patients with melanoma that has spread from where it started to nearby tissue or lymph nodes or to other places in the body. Aldesleukin may stimulate a person's white blood cells ...	PRIMARY OBJECTIVES: I. To identify whether the addition of the peptide vaccine to high dose interleukin (IL)-2 (aldesleukin) can result in a clinical response rate which may be superior to that found in similar patients treated with high dose IL-2 alone. SECONDARY OBJECTIVES: I. To evaluate the toxicity profile of p...	Recurrent Melanoma Stage IIIA Skin Melanoma Stage IIIB Skin Melanoma Stage IIIC Skin Melanoma Stage IV Skin Melanoma		null	2	arm 1: Patients receive aldesleukin IV over 15 minutes every 8 hours for 12 doses. Treatment repeats every 3 weeks for 2 courses in the absence of disease progression or unacceptable toxicity. Patients with stable or responding disease 3 weeks after completing 2 courses may receive a maximum of 12 additional courses. P...	[ 0, 0 ]	6	[ 2, 2, 0, 10, 10, 10 ]	intervention 1: Given IV intervention 2: Given SC intervention 3: Given SC intervention 4: Ancillary studies intervention 5: Ancillary studies intervention 6: Correlative studies	intervention 1: Aldesleukin intervention 2: gp100 Antigen intervention 3: Montanide ISA 51 VG intervention 4: Quality-of-Life Assessment intervention 5: Questionnaire Administration intervention 6: Laboratory Biomarker Analysis	19	Birmingham \| Alabama \| United States \| -86.80249 \| 33.52066 Scottsdale \| Arizona \| United States \| -111.89903 \| 33.50921 Riverside \| California \| United States \| -117.39616 \| 33.95335 Aurora \| Colorado \| United States \| -104.83192 \| 39.72943 Lakeland \| Florida \| United States \| -81.9498 \| 28.03947 Atlanta \| Georgia \| U...	178	0	0	0	NCT00019682	1COMPLETED	2011-05-01	1999-12-01	National Cancer Institute (NCI)	0NIH	false	false	false	null	0	0	0	0	0	0
[ 3 ]	30	NA	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	true	RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells, but also damages normal cells in the developing brains of children. Combining low-dose radiation therapy in combination with chemotherapy should be effective in treating medulloblastoma while avoiding the long-term side effects of giving higher...	OBJECTIVES: * By giving reduced dose craniospinal radiation followed by nine cycles of maintenance chemotherapy comprised of alternating cycles of lomustine, cisplatin, and vincristine alternating with cyclophosphamide and etoposide, we will reduce the late effects of higher dose radiation in children while maintainin...	Brain Tumors Central Nervous System Tumors Medulloblastoma	average risk medulloblastoma craniospinal radiotherapy newly diagnosed	null	1	arm 1: All subjects will undergo routine surgical staging of their tumor. Treatment must begin within 28 days of surgery. Craniospinal Radiation therapy will last for 6 weeks, five days per week. Once a week during radiation, subjects will also be treated with vincristine. 4 weeks after radiation and vincristine treatm...	[ 0 ]	6	[ 0, 0, 0, 0, 0, 4 ]	intervention 1: Given at a dose of 70mg/m2 by intravenous (IV) infusion over 8 hours on day 0 of each cycle (Regimen A only). intervention 2: Given at a dose of 1g/m2/day by IV infusion on days 0 and 1 of a 6-week cycle. Administration of cyclophosphamide will always be preceded by prehydration and Mesna (Regimen B onl...	intervention 1: Cisplatin intervention 2: Cyclophosphamide intervention 3: Etoposide intervention 4: Lomustine intervention 5: Vincristine intervention 6: Craniospinal Radiation	3	Palo Alto \| California \| United States \| -122.14302 \| 37.44188 Atlanta \| Georgia \| United States \| -84.38798 \| 33.749 Philadelphia \| Pennsylvania \| United States \| -75.16362 \| 39.95238	28	0	0	0	NCT00031590	6TERMINATED	2011-05-01	2001-04-01	Children's Hospital of Philadelphia	7OTHER	false	false	false	null	0	0	0	0	0	0
[ 3 ]	6	NA	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	false	RATIONALE: Photopheresis allows patient white blood cells to be treated with ultraviolet (UV) light and drugs outside the body to inactivate T cells. Pentostatin may suppress the immune system and reduce the chance of developing graft-versus-host disease (GVHD) following bone marrow transplantation. Combining photopher...	OBJECTIVES: * Determine the rate of stable engraftment of donor cells in patients with relapsed non-Hodgkin's or Hodgkin's lymphoma treated with a reduced toxicity conditioning regimen followed by allogeneic (sibling or unrelated) bone marrow transplantation. * Determine the extent and duration of acute and chronic gr...	Lymphoma	recurrent adult Hodgkin lymphoma recurrent adult diffuse large cell lymphoma recurrent adult diffuse mixed cell lymphoma recurrent adult diffuse small cleaved cell lymphoma recurrent adult Burkitt lymphoma recurrent adult immunoblastic large cell lymphoma recurrent adult lymphoblastic lymphoma recurrent grade 1 follicu...	null	1	arm 1: Reduced toxicity conditioning regimen followed by allogeneic sibling or unrelated transplant. The conditioning regimen includes Extracorporeal Photopheresis, Pentostatin and total body irradiation (TBI). After allogeneic bone marrow transplantation, cyclosporin, mycophenolate mofetil (MMF), and methotrexate (MTX...	[ 0 ]	7	[ 3, 0, 4, 3, 0, 0, 0 ]	intervention 1: Day -7 to -4: Extracorporeal Photopheresis may be given as an outpatient therapy on two consecutive days any time between days -7 to -4. This must be performed on UVAR or XTS photopheresis machines (Therakos, Inc.) according to standard procedure as per manufacturer's guidelines. intervention 2: Day -3,...	intervention 1: Extracorporeal Photopheresis intervention 2: Pentostatin intervention 3: Total body irradiation (TBI) intervention 4: Allogeneic bone marrow transplantation intervention 5: Cyclosporin (CSA) intervention 6: Mycophenolate mofetil (MMF) intervention 7: Methotrexate (MTX)	19	Aurora \| Colorado \| United States \| -104.83192 \| 39.72943 Boulder \| Colorado \| United States \| -105.27055 \| 40.01499 Colorado Springs \| Colorado \| United States \| -104.82136 \| 38.83388 Denver \| Colorado \| United States \| -104.9847 \| 39.73915 Denver \| Colorado \| United States \| -104.9847 \| 39.73915 Denver \| Colorado \| U...	6	0	0	0	NCT00057954	6TERMINATED	2011-05-01	2005-11-09	Eastern Cooperative Oncology Group	5NETWORK	false	false	false	null	0	0	0	0	0	0
[ 3 ]	39	NA	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	false	RATIONALE: Drugs used in chemotherapy, such as doxorubicin and gemcitabine, use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving doxorubicin together with gemcitabine works in t...	OBJECTIVES: * Determine the response rate of patients with locally recurrent or metastatic unresectable renal cell cancer with sarcomatoid features treated with doxorubicin and gemcitabine. * Determine the progression-free survival and overall survival of patients treated with this regimen. * Determine the toxic effec...	Metastatic Renal Cell Carcinoma Renal Cell Carcinoma With Sarcomatoid Features	Sarcomatoid Gemcitabine Doxorubicin Renal cell cancer Kidney cancer	null	1	arm 1: Doxorubicin was given at 50 mg/m² by IV slow push, followed by gemcitabine 1500 mg/m² IV infusion over 30 minutes on day 1. Patients will receive G-CSF at a subcutaneous dose of 5mcg/kg/day on days 2 or 3 to 10 or neulasta at a dose of 6mg on day 2. Growth factor must be administered as close as possible to 24 h...	[ 0 ]	4	[ 0, 0, 0, 0 ]	intervention 1: Doxorubicin: 50 mg/m² IV slow push followed by gemcitabine 1500 mg/m² IV infusion over 30 minutes on day 1. Cycles repeat every 2 weeks. intervention 2: Doxorubicin: 50 mg/m² IV slow push followed by gemcitabine 1500 mg/m² IV infusion over 30 minutes on day 1. Cycles repeat every 2 weeks. intervention 3...	intervention 1: Doxorubicin intervention 2: Gemcitabine intervention 3: G-CSF (granulocyte-colony stimulating factor) intervention 4: Neulasta	92	Los Angeles \| California \| United States \| -118.24368 \| 34.05223 Aurora \| Colorado \| United States \| -104.83192 \| 39.72943 Aurora \| Illinois \| United States \| -88.32007 \| 41.76058 Chicago \| Illinois \| United States \| -87.65005 \| 41.85003 Chicago \| Illinois \| United States \| -87.65005 \| 41.85003 Chicago \| Illinois \| Uni...	38	0	0	0	NCT00068393	1COMPLETED	2011-05-01	2004-02-24	Eastern Cooperative Oncology Group	5NETWORK	false	false	false	null	0	0	0	0	0	0
[ 3 ]	4	NA	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	false	RATIONALE: Cyclosporine may help the immune system slow the growth of angioimmunoblastic T-cell lymphoma. PURPOSE: This phase II trial is studying how well cyclosporine works in treating patients with recurrent or refractory angioimmunoblastic T-cell lymphoma.	OBJECTIVES: Primary * Determine the response rate (complete and partial) in patients with recurrent or refractory angioimmunoblastic T-cell lymphoma treated with cyclosporine. Secondary * Determine the disease-free, progression-free, and overall survival of patients treated with this drug. * Determine the toxicity ...	Lymphoma	angioimmunoblastic T-cell lymphoma	null	1	arm 1: High dose cyclosporine weeks 1-6, then maintenance dose cyclosporine weeks 7-36. If CR, PR, or SD at week 36 evaluation, treatment is complete. If progression occurs during weeks 7-36, patients will re-register to Step 2 at time of PD and begin high dose therapy (weeks 1-6), followed by maintenance therapy (week...	[ 0 ]	1	[ 0 ]	intervention 1: Cyclosporine doses will be based on actual body weight unless actual body weight is \> 15 kg higher than the ideal body weight. Cyclosporine dose will be adjusted to maintain a trough whole blood level of 250-450 ng/mL during the high dose period (weeks 1 -6, starting dose will begin at cyclosporine 3 m...	intervention 1: cyclosporine	23	Stanford \| California \| United States \| -122.16608 \| 37.42411 Aurora \| Illinois \| United States \| -88.32007 \| 41.76058 Berwyn \| Illinois \| United States \| -87.79367 \| 41.85059 Chicago \| Illinois \| United States \| -87.65005 \| 41.85003 Chicago \| Illinois \| United States \| -87.65005 \| 41.85003 Chicago \| Illinois \| United ...	3	0	0	0	NCT00070291	6TERMINATED	2011-05-01	2006-01-24	Eastern Cooperative Oncology Group	5NETWORK	false	false	false	null	0	0	0	0	0	0
[ 3 ]	130	RANDOMIZED	PARALLEL	0TREATMENT	0NONE	false	0ALL	true	Although some doctors favor starting anti-HIV treatment as soon as possible after patients learn they are infected, it is not known if treatment for recently infected patients results in long-term benefits or harm. The purpose of this study is to learn whether or not people should take anti-HIV drugs when they are firs...	Combination antiretroviral therapy has resulted in significantly decreased morbidity and mortality, incidence of opportunistic infections, and hospitalizations in HIV infected people. However, because of long-term toxicities associated with long-term use of antiretrovirals and the persistence of virus in latent reservo...	HIV Infections	Acute Infection Treatment Naive	null	2	arm 1: IT (immediate treatment) arm participants received emtricitabine/tenofovir disoproxil fumarate once daily and lopinavir/ritonavir twice daily arm 2: DT (deferred treatment) arm participants received no treatment	[ 1, 4 ]	2	[ 0, 0 ]	intervention 1: once daily intervention 2: twice daily	intervention 1: Emtricitabine/ tenofovir disoproxil fumarate intervention 2: Lopinavir/Ritonavir	27	San Diego \| California \| United States \| -117.16472 \| 32.71571 San Francisco \| California \| United States \| -122.41942 \| 37.77493 Torrance \| California \| United States \| -118.34063 \| 33.83585 Aurora \| Colorado \| United States \| -104.83192 \| 39.72943 Miami \| Florida \| United States \| -80.19366 \| 25.77427 Atlanta \| Georg...	130	0	0	0	NCT00090779	6TERMINATED	2011-05-01	2005-01-01	Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections	5NETWORK	false	false	false	null	0	0	0	0	0	0
[ 3 ]	32	RANDOMIZED	PARALLEL	0TREATMENT	0NONE	false	0ALL	false	RATIONALE: Drugs used in chemotherapy, such as pemetrexed disodium, gemcitabine, and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. It is not yet known w...	OBJECTIVES: Primary * Estimate the response rates in patients with advanced malignant mesothelioma of the pleura treated with pemetrexed disodium combined with either gemcitabine or carboplatin. Secondary * Assess the toxic effects of these regimens in these patients. * Estimate survival time in patients treated wi...	Mesothelioma	advanced malignant mesothelioma recurrent malignant mesothelioma	null	2	arm 1: Pemetrexed disodium 500 mg/m2 IV over 10 minutes and carboplatin to area under the curve (AUC) 5 IV over 30 minutes on day 1 of a 21-day cycle. arm 2: Pemetrexed disodium 500 mg/m2 IV over 10 minutes on day 1 and gemcitabine 1000 mg/m2 IV over 30 minutes on days 1 and 8 of a 21-day cycle.	[ 0, 0 ]	3	[ 0, 0, 0 ]	intervention 1: 500 mg/m2 IV over 10 minutes on day 1 of a 21-day cycle intervention 2: 1000 mg/m2 IV over 30 minutes on days 1 and 8 of a 21-day cycle intervention 3: Given by IV over 30 minutes at an area under the curve (AUC) of 5 on day 1 of a 21-day cycle	intervention 1: pemetrexed disodium intervention 2: gemcitabine hydrochloride intervention 3: carboplatin	115	Norwich \| Connecticut \| United States \| -72.07591 \| 41.52426 Lewes \| Delaware \| United States \| -75.13935 \| 38.77456 Newark \| Delaware \| United States \| -75.74966 \| 39.68372 Jacksonville \| Florida \| United States \| -81.65565 \| 30.33218 Atlanta \| Georgia \| United States \| -84.38798 \| 33.749 Aurora \| Illinois \| United St...	29	0	0	0	NCT00101283	1COMPLETED	2011-05-01	2006-02-23	Eastern Cooperative Oncology Group	5NETWORK	false	false	false	null	0	0	0	0	0	0
[ 2 ]	34	NON_RANDOMIZED	PARALLEL	0TREATMENT	0NONE	false	0ALL	null	The purposes of this study are: * To determine the maximum tolerated dose (MTD) for the combination of oral vorinostat and bortezomib in participants with advanced multiple myeloma * To assess the safety and tolerability of this regimen and to document the participant's clinical status (by anti-tumor activity) for thi...	null	Multiple Myeloma		null	6	arm 1: Vorinostat capsules given twice daily (b.i.d.); bortezomib injection given on Days 4, 8, 11, and 15 of each cycle. arm 2: Vorinostat capsules given b.i.d.; bortezomib injection given on Days 4, 8, 11, and 15 of each cycle. arm 3: Vorinostat given once daily (q.d.); bortezomib given on Days 1, 4, 8, and 11 of eac...	[ 0, 0, 0, 0, 0, 0 ]	2	[ 0, 0 ]	intervention 1: Vorinostat capsules. Treatment in 21 day cycles (participants receive vorinostat for 14 days followed by a 7 day break). intervention 2: Bortezomib injection. Given twice weekly for 2 weeks with a 1 week break. Treatment in 21 day cycles.	intervention 1: vorinostat intervention 2: bortezomib	0	null	34	0	0	0	NCT00111813	1COMPLETED	2011-05-01	2005-09-01	Merck Sharp & Dohme LLC	4INDUSTRY	false	false	false	null	0	0	0	0	0	0
[ 0 ]	164	NON_RANDOMIZED	PARALLEL	0TREATMENT	0NONE	false	0ALL	true	The purpose of this research study is to study the effects (good and bad) of bevacizumab alone, bevacizumab with low-dose continuous chemotherapy (called metronomic chemotherapy), or bevacizumab with capecitabine, on you and your cancer. The goals of the study will be to: * Examine the safety of these drugs * See how ...	This study is broken into 4 groups (A, B, C, and D). Enrollment closed to all groups in May 2008. The first forty subjects (Group A) in this study were treated with Bevacizumab only, which is given through a vein over 1-2 hours every 3 weeks, for a total of approximately 12 months (17 cycles). Each cycle consists of 3...	Breast Cancer	Bevacizumab Metronomic Chemotherapy Breast Cancer Stages II-III Invasive breast cancer stages II-III	null	4	arm 1: Bevacizumab Alone arm 2: Bevacizumab with cyclophosphamide and methotrexate arm 3: capecitabine, 14 days on/7 days off scheduling, and bevacizumab arm 4: capecitabine 7 days on/7 days off scheduling, and bevacizumab	[ 0, 0, 0, 0 ]	4	[ 0, 0, 0, 0 ]	intervention 1: Group A: Once every 3 weeks for 12 months Group B: Once every 3 weeks for 12 months intervention 2: Once a day for 6 months intervention 3: Twice daily for the first two days of every week for 6 months intervention 4: Capecitabine: 2000 mg/m2 a day, on Days 1-14 of a 21 day cycle, for at total of 6 cycl...	intervention 1: Bevacizumab intervention 2: Cyclophosphamide intervention 3: Methotrexate intervention 4: Capecitabine	5	San Francisco \| California \| United States \| -122.41942 \| 37.77493 Indianapolis \| Indiana \| United States \| -86.15804 \| 39.76838 Boston \| Massachusetts \| United States \| -71.05977 \| 42.35843 Boston \| Massachusetts \| United States \| -71.05977 \| 42.35843 Durham \| North Carolina \| United States \| -78.89862 \| 35.99403	162	0	0	0	NCT00121134	1COMPLETED	2011-05-01	2005-06-01	Harold J. Burstein, MD, PhD	7OTHER	false	false	false	null	0	0	0	0	0	0
[ 0 ]	84	RANDOMIZED	PARALLEL	1PREVENTION	4QUADRUPLE	true	0ALL	false	The purpose of this study is to determine whether cardiovascular disease (CVD) risk markers, β-cell function, and insulin sensitivity can be improved by targeting mechanisms of both diabetes and CVD - using an antioxidant, an angiotensin II receptor blocker (ARB), or an anti-inflammatory agent - in patients with impair...	Diabetes is a common, major health problem in the United States, and it significantly increases the risk of developing heart disease, which is the leading cause of death. Research studies have shown that the risk of heart disease is increased, even in the "pre-diabetes" or impaired glucose tolerance (IGT) stage, before...	Impaired Glucose Tolerance Prediabetic State	Prediabetic state Cardiovascular disease Diabetes Glucose intolerance	null	4	arm 1: Aspirin (ASA) arm 2: Olmesartan (ARB) arm 3: Alpha lipoic acid (ALA) arm 4: Aspirin placebo once a day Olmesartan placebo once a day Alpha lipoic acid placebo twice a day	[ 1, 1, 1, 2 ]	4	[ 0, 0, 0, 0 ]	intervention 1: 325 mg PO QD intervention 2: 600 mg PO BID intervention 3: 40 mg PO QD intervention 4: Identical placebo for each active comparator: placebo aspirin 325 mg PO QD; placebo for alpha lipoic acid 600 mg PO BID; placebo for olmesartan 40 mg PO QD	intervention 1: Aspirin intervention 2: Alpha lipoic acid intervention 3: Olmesartan intervention 4: Placebo	2	Atlanta \| Georgia \| United States \| -84.38798 \| 33.749 Atlanta \| Georgia \| United States \| -84.38798 \| 33.749	84	0	0	0	NCT00122447	1COMPLETED	2011-05-01	2005-05-01	Emory University	7OTHER	false	false	false	null	0	0	0	0	0	0
[ 3, 4 ]	24	RANDOMIZED	SINGLE_GROUP	0TREATMENT	4QUADRUPLE	true	0ALL	true	This study examined the cognitive and behavioral differences in children who have an autism spectrum disorder (ASD) with or without additional symptoms of ADHD. The study also examined the effectiveness of a range of doses of methylphenidate in improving cognitive and behavioral outcomes in children with both ASD and A...	Attention Deficit Hyperactivity Disorder (ADHD) is a major comorbid psychiatric disorder in children with Autism Spectrum Disorders (ASD) that significantly undermines behavioral, social, and emotional adjustment. Although the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) does not specifically allow fo...	Autism Attention Deficit Disorder With Hyperactivity		null	4	arm 1: 24 Participants with ASD-ADHD underwent 1 week of placebo in the MPH treatment phase arm 2: 24 Participants with ASD-ADHD underwent 1 week at a low dose of Methylphenidate-extended release and Methylphenidate-immediate release in the MPH treatment phase arm 3: 24 Participants with ASD-ADHD underwent 1 week at a ...	[ 2, 1, 1, 1 ]	3	[ 0, 0, 10 ]	intervention 1: Methylphenidate-extended release was taken in the morning of the MPH treatment trial. Each participant underwent 1 week of the each of the doses as determined by body weight. The lower body weight group (20 to 24 kg/44 to 52.8 lbs) took 10 mg Ritalin LA to 20 mg. The medium body weight group (25 to 33 k...	intervention 1: Methylphenidate-extended release intervention 2: Methylphenidate-immediate release intervention 3: Placebo	1	Houston \| Texas \| United States \| -95.36327 \| 29.76328	96	0	0	0	NCT00178503	1COMPLETED	2011-05-01	2005-09-01	The University of Texas Health Science Center, Houston	7OTHER	false	false	false	null	0	0	0	0	0	0
[ 3 ]	6	NON_RANDOMIZED	SINGLE_GROUP	0TREATMENT	0NONE	false	1FEMALE	null	The purpose of the study is to assess the safety and determine the effects of the hormone prolactin on lactation (breast milk production).	The efficacy of recombinant human prolactin (r-hPRL) for treatment of primary lactation insufficiency in women with prolactin deficiency, either congenital or acquired, will be examined. Subjects will participate in an open-label study of r-hPRL administration for prolactin deficiency. On study day 1, subjects will be ...	Lactation	Lactation Breastfeeding Prolactin Primary lactation insufficiency	null	1	arm 1: Open label twice daily recombinant human prolactin	[ 0 ]	1	[ 0 ]	intervention 1: None	intervention 1: Recombinant Human Prolactin	1	Boston \| Massachusetts \| United States \| -71.05977 \| 42.35843	5	0	0	0	NCT00181623	1COMPLETED	2011-05-01	2005-01-01	Massachusetts General Hospital	7OTHER	false	false	false	null	0	0	0	0	0	0
[ 4 ]	46	RANDOMIZED	PARALLEL	0TREATMENT	3TRIPLE	false	0ALL	true	The primary aim of this proposal is to conduct a preliminary controlled trial of valproate and risperidone in children ages 3-7 yr. with bipolar disorders. A secondary aim is to carefully characterize these subjects using clinical rating scales and develop pilot data on a very young cohort of children with bipolar diso...	It is now recognized that pediatric bipolar disorders are highly prevalent and that they seriously disrupt the lives of children and adolescents, with studies showing poorer academic performance, disturbed interpersonal relationships, increased rates of substance abuse, legal difficulties, multiple hospitalizations, an...	Bipolar Disorder	child adolescent bipolar disorder	null	3	arm 1: VPA was administered in liquid form, matched for taste and color with the placebo. Medication was administered in a double-blinded manner on a twice-daily basis. Patients randomized to VPA were administered an initial dose of 10 mg/kg/day on a twice daily schedule beginning on day 0. VPA levels were adjusted to ...	[ 1, 1, 2 ]	3	[ 0, 0, 10 ]	intervention 1: liquid, BID dosing. intervention 2: liquid, BID dosing. intervention 3: liquid, BID dosing.	intervention 1: Risperidone oral solution intervention 2: Valproate Oral Solution intervention 3: Placebo	2	Cincinnati \| Ohio \| United States \| -84.51439 \| 39.12711 Milwaukee \| Wisconsin \| United States \| -87.90647 \| 43.0389	46	0	0	0	NCT00221403	1COMPLETED	2011-05-01	2004-09-01	Children's Hospital Medical Center, Cincinnati	7OTHER	false	false	false	null	0	0	0	0	0	0
[ 4 ]	150	RANDOMIZED	PARALLEL	0TREATMENT	2DOUBLE	false	0ALL	true	This study will test the hypothesis that the administration of a xanthine oxidase inhibitor (allopurinol) will prevent thiazide-induced hyperuricemia, which will result in better blood pressure (BP) control in African Americans.	Thiazide diuretics when used in the treatment of hypertension are associated with many metabolic side effects, including hyperuricemia, gout, insulin resistance, and hyperlipidemia. Each of these conditions is already highly prevalent in African Americans. Our hypothesis is that thiazide-induced hyperuricemia decreases...	Cardiovascular Diseases Heart Diseases Hypertension		null	2	arm 1: Chlorthalidone 25 mg and Potassium Chloride 40-50meq were given daily for 5 weeks before baseline visit for testing. After baseline testing was completed, Allopurinol 300mg daily was added for 8-10 weeks at which time testing was repeated. arm 2: Chlorthalidone 25 mg and Potassium Chloride 40-50meq were given da...	[ 1, 2 ]	4	[ 0, 0, 0, 0 ]	intervention 1: Allopurinol (300 mg capsule) was given for 8-10 weeks compared to placebo group after initial baseline testing. After two weeks on the Allopurinol, a serum uric acid level was obtained. If the uric acid level was greater than 5.5, the Allopurinol dosage was increased to 600mg (two 300 mg capsules)for th...	intervention 1: Allopurinol intervention 2: Placebo intervention 3: Chlorthalidone intervention 4: Potassium chloride	1	Gainesville \| Florida \| United States \| -82.32483 \| 29.65163	142	0	0	0	NCT00241839	1COMPLETED	2011-05-01	2005-08-01	University of Florida	7OTHER	false	false	false	null	0	0	0	0	0	0
[ 3 ]	5	NA	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	null	Sorafenib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the cancer. This phase II trial is studying how well sorafenib works in treating patients with relapsed chronic lymphocytic leukemia.	PRIMARY OBJECTIVES: I. Determine the objective response rate in patients with recurrent chronic lymphocytic leukemia (CLL) treated with sorafenib. II. Determine the toxicity in patients treated with sorafenib. SECONDARY OBJECTIVES: I. Correlate bone marrow angiogenesis, CLL tumor cell expression of vascular endothe...	Refractory Chronic Lymphocytic Leukemia Stage I Chronic Lymphocytic Leukemia Stage II Chronic Lymphocytic Leukemia Stage III Chronic Lymphocytic Leukemia Stage IV Chronic Lymphocytic Leukemia		null	1	arm 1: Patients receive oral sorafenib twice daily on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.	[ 0 ]	1	[ 0 ]	intervention 1: Given orally	intervention 1: sorafenib tosylate	1	Chicago \| Illinois \| United States \| -87.65005 \| 41.85003	5	0	0	0	NCT00303966	6TERMINATED	2011-05-01	2005-11-01	National Cancer Institute (NCI)	0NIH	false	false	false	null	0	0	0	0	0	0
[ 3 ]	39	RANDOMIZED	PARALLEL	0TREATMENT	0NONE	false	0ALL	false	The goal of this clinical research study is to see if Leukine(R) (sargramostim) improves the effectiveness of the pneumococcal vaccine, a medicine used to prevent pneumococcal pneumonia, in patients with chronic lymphocytic leukemia (CLL).	Sargramostim (also commonly called granulocyte macrophage colony stimulating factor - GM-CSF) is a medication used to stimulate the bone marrow production of white blood cells before a stem cell transplant, after chemotherapy or after a bone marrow transplant. Pneumococcal vaccine is a medication used to prevent infect...	Leukemia	Chronic Lymphocytic Leukemia Leukemia Sargramostim Pneumococcal Pneumonia Pneumococcal Vaccine Prevnar GM-CSF CLL	null	2	arm 1: Vaccine subcutaneously + GM-CSF (3 Doses of 250 mg subcutaneously) given either Pre Vaccine at Day -7, Day -1 and Day 0 (day of pneumococcal vaccine) or Post Vaccine given at Day 0, Day +3 and Day +7. arm 2: First vaccine dose subcutaneously, Day 0.	[ 0, 0 ]	2	[ 0, 2 ]	intervention 1: Starting with 3 doses of 250 micrograms subcutaneously, either pre or post vaccine. For pre vaccine, GM-CSF on days -7 (+ 1 day) and -3 (+ 1 day), in the week prior to vaccination for pre-vaccination immune priming; 3rd dose on the day of vaccination (day 0); and for post-vaccine GM-CSF given simultaneo...	intervention 1: Sargramostim (GM-CSF) intervention 2: Pneumococcal Vaccine	1	Houston \| Texas \| United States \| -95.36327 \| 29.76328	32	0	0	0	NCT00323557	1COMPLETED	2011-05-01	2004-06-01	M.D. Anderson Cancer Center	7OTHER	false	false	false	null	0	0	0	0	0	0
[ 3 ]	29	NA	SINGLE_GROUP	0TREATMENT	0NONE	false	2MALE	null	This phase II trial is studying how well vorinostat works in treating patients with progressive metastatic prostate cancer. Drugs used in chemotherapy, such as vorinostat, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Vorinostat may also stop th...	PRIMARY OBJECTIVES: I. To evaluate the efficacy of oral SAHA in patients with castrate metastatic prostate cancer who have progressed on one prior chemotherapy, as measured by the proportion of patients not progressed at 6 months. SECONDARY OBJECTIVES: I. To evaluate the safety of oral SAHA in patients with castrate...	Recurrent Prostate Cancer Stage IV Prostate Cancer		null	1	arm 1: Patients receive oral vorinostat (SAHA) once daily on days 1-21. Treatment repeats every 21 days for at least 4 courses in the absence of disease progression or unacceptable toxicity. Patients who achieve complete response (CR) after 4 courses receive an additional 3 courses. All other patients may continue trea...	[ 0 ]	2	[ 0, 10 ]	intervention 1: Given orally intervention 2: Correlative studies	intervention 1: vorinostat intervention 2: laboratory biomarker analysis	1	Ann Arbor \| Michigan \| United States \| -83.74088 \| 42.27756	29	0	0	0	NCT00330161	1COMPLETED	2011-05-01	2006-03-01	National Cancer Institute (NCI)	0NIH	false	false	false	null	0	0	0	0	0	0
[ 3 ]	15	NON_RANDOMIZED	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	false	The goal of this clinical research study is to learn if sunitinib malate (SU011248) can help to control VHL. The safety of this drug will also be studied. Primary objectives: * Evaluate safety of treatment with SU011248/sunitinib malate (50 mg daily dose for 4 weeks, then 2 weeks off) for 6 months in patients with Vo...	Sunitinib malate is designed to block pathways that control important events such as the growth of blood vessels that are essential for the growth of cancer. Before you can start treatment on this study, you will have what are called "screening tests." These tests will help the doctor decide if you are eligible to tak...	Von Hippel-Lindau Syndrome Renal Cell Carcinoma Hemangioblastoma	VHL Syndrome Von Hippel-Lindau Syndrome VHL Disease Kidney Retina Brain Spinal cord Pancreas Inner ear Cysts Tumors Sunitinib Malate SU011248 Sutent VHL Sunitinib Renal cell carcinoma Hemangioblastoma Endothelium	null	1	arm 1: 50 mg/day orally for 4 weeks	[ 0 ]	1	[ 0 ]	intervention 1: 50 mg/day orally for 4 weeks, no treatment for 2 weeks (6 weeks = 1 cycle).	intervention 1: SU011248	1	Houston \| Texas \| United States \| -95.36327 \| 29.76328	15	0	0	0	NCT00330564	6TERMINATED	2011-05-01	2006-05-01	M.D. Anderson Cancer Center	7OTHER	false	false	false	null	0	0	0	0	0	0
[ 0 ]	31	RANDOMIZED	PARALLEL	0TREATMENT	3TRIPLE	true	1FEMALE	true	The purpose of the study is to determine how effective Botox is in reducing the amount of urine leaked and which dose of Botox is more effective and safe in those who have urinary urge incontinence.	A multi-center clinical trial of Botulinum-A Toxin (Botox) for refractory urge incontinence.	Urinary Incontinence		null	2	arm 1: Placebo arm 2: Botox	[ 2, 0 ]	2	[ 0, 0 ]	intervention 1: Injected intervention 2: Injected	intervention 1: Botox intervention 2: Placebo	3	Sacramento \| California \| United States \| -121.4944 \| 38.58157 Boston \| Massachusetts \| United States \| -71.05977 \| 42.35843 Durham \| North Carolina \| United States \| -78.89862 \| 35.99403	31	0	0	0	NCT00345332	1COMPLETED	2011-05-01	2005-10-01	University of Rochester	7OTHER	false	false	false	null	0	0	0	0	0	0
[ 2, 3 ]	38	NA	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	true	The purposes of this study are: 1. To assess the maximum tolerated dose of low-dose UART(Upper Abdominal Radiation Therapy ) or WART(Whole Abdominal Radiation Therapy) given in combination with standard fixed dose-rate Gemcitabine in patients with advanced gastrointestinal (GI) or ovarian tumors (Phase I). 2. To asses...	Before entering this study the doctor will examine the patient and order blood tests. These tests will use approximately 10 ml of blood. Blood work should be done within 3 weeks prior to treatment.. Women of child-bearing potential are required to have a pregnancy test done within 7 days prior to the start of treatment...	Gastrointestinal Neoplasms Ovarian Neoplasms	GI tumors Locally Advanced Metastatic Hepatobiliary Ovary	null	1	arm 1: Gemcitabine will be given at 1250 mg per meter squared over 2 hours days 1 and 8 of a 21 day cycle for a total of 4 cycles. Radiation: External Radiation Therapy The total dose would be 19.2 Gy divided over 32 fractions twice a day, on day 1 and day 8 after chemotherapy.	[ 0 ]	1	[ 0 ]	intervention 1: Gemcitabine will be given at 1250 mg per meter squared over 2 hours days 1 and 8 of a 21 day cycle for a total of 4 cycles. Radiation:External Radiation Therapy The total dose would be 19.2 Gy divided over 32 fractions twice a day, on day 1 and day 8 after chemotherapy. \\Radiation is the experiment...	intervention 1: Gemcitabine	2	Baltimore \| Maryland \| United States \| -76.61219 \| 39.29038 Hamilton \| Ontario \| Canada \| -79.84963 \| 43.25011	38	0	0	0	NCT00390182	1COMPLETED	2011-05-01	2003-10-01	University of Maryland, Baltimore	7OTHER	false	false	false	null	0	0	0	0	0	0
[ 3 ]	24	NA	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	true	RATIONALE: Giving total-body irradiation and chemotherapy, such as fludarabine and thiotepa, before a donor stem cell transplant helps stop the growth of cancer or abnormal cells. It also helps stop the patient's immune system from rejecting the donor's stem cells. When healthy stem cells from a donor are infused into ...	OBJECTIVES: Primary * Determine the incidence of disease-free survival at 1 year in patients with acute or chronic myeloid leukemias undergoing T-cell-depleted hematopoietic stem cell transplantation from HLA-C mismatched, unrelated donors. Secondary * Determine the incidence of disease relapse at 1 year in patient...	Leukemia Myelodysplastic Syndromes	adult acute myeloid leukemia with 11q23 (MLL) abnormalities adult acute myeloid leukemia in remission childhood acute myeloid leukemia in remission de novo myelodysplastic syndromes previously treated myelodysplastic syndromes adult acute myeloid leukemia with inv(16)(p13;q22) adult acute myeloid leukemia with t(15;17)...	null	1	arm 1: None	[ 0 ]	5	[ 2, 0, 0, 3, 4 ]	intervention 1: Rabbit thymoglobulin will be given intravenously at a dose of 2.5 mg/kg on days -5,-4, -3, and -2. The first dose of thymoglobulin will be given over six (6) hours and subsequent doses over four (4) or more hours as tolerated or, per institutional anti-thymocyte globulin (ATG) administration guidelines....	intervention 1: anti-thymocyte globulin intervention 2: fludarabine phosphate intervention 3: thiotepa intervention 4: peripheral blood stem cell transplantation intervention 5: total-body irradiation	9	Tampa \| Florida \| United States \| -82.45843 \| 27.94752 Atlanta \| Georgia \| United States \| -84.38798 \| 33.749 Indianapolis \| Indiana \| United States \| -86.15804 \| 39.76838 Minneapolis \| Minnesota \| United States \| -93.26384 \| 44.97997 St Louis \| Missouri \| United States \| -90.19789 \| 38.62727 Columbus \| Ohio \| United S...	24	0	0	0	NCT00392782	6TERMINATED	2011-05-01	2005-07-01	Masonic Cancer Center, University of Minnesota	7OTHER	false	false	false	null	0	0	0	0	0	0
[ 4 ]	131	RANDOMIZED	PARALLEL	0TREATMENT	4QUADRUPLE	false	0ALL	true	The primary aims of this study are to assess tolerability of ziprasidone dose escalation to 320 milligrams per day (mg/d) compared to continued standard treatment (placebo) as measured by the Side Effect Checklist, Simpson Angus Scale for Extrapyramidal Symptoms (SAS), Barnes Akathisia Scale (BAS), serum prolactin conc...	null	Schizophrenia	Schizophrenia	null	2	arm 1: Participants with schizophrenia or schizoaffective disorder who remain symptomatic despite treatment with ziprasidone 160 mg/d for at least 3 weeks will be instructed to take ziprasidone oral capsule twice daily added to their regular open-label ziprasidone dose (total of 240 mg/d). After the first week, the stu...	[ 0, 2 ]	3	[ 0, 0, 0 ]	intervention 1: Participants will be instructed to take one study capsule of ziprasidone orally twice daily (80 mg/d). After the first week, the study drug will be increased to two capsules twice daily (160 mg/d). intervention 2: Participants will be instructed to take one study capsule of matching placebo orally twice...	intervention 1: Ziprasidone 80-160 mg/d intervention 2: Placebo intervention 3: Ziprasidone 160 mg/d	9	Augusta \| Georgia \| United States \| -81.97484 \| 33.47097 Fall River \| Massachusetts \| United States \| -71.15505 \| 41.70149 Grand Rapids \| Michigan \| United States \| -85.66809 \| 42.96336 Albuquerque \| New Mexico \| United States \| -106.65114 \| 35.08449 Brooklyn \| New York \| United States \| -73.94958 \| 40.6501 New York \| ...	309	0	0	0	NCT00403546	1COMPLETED	2011-05-01	2006-01-01	Donald C. Goff, MD	7OTHER	false	false	false	null	0	0	0	0	0	0
[ 5 ]	40	RANDOMIZED	PARALLEL	0TREATMENT	1SINGLE	true	0ALL	false	The purpose of this study is to evaluate Pulmozyme® (dornase) as compared to a standard ear drop Floxin® (ofloxicin) to dissolve clogged tubes. This study will monitor the use of the new drug for any problems related to the medication. Patients are being asked to be in this study because they had tubes placed for the t...	The success in treating blocked tubes may relate to the ability to dissolve the material clogging the tube as well as dealing with the thick fluid in the middle-ear. The reasoning behind this study is that the use of Pulmozyme® may be able to treat both of these problems. Pulmozyme® was approved by the FDA in 1994 for ...	Otitis Media	clogged ear tubes	null	2	arm 1: dornase alfa - Pulmozyme®: 5 drops twice daily for 7 days to the affected ear. arm 2: Ofloxin : 5 drops twice daily for 7 days to the affected ear.	[ 1, 1 ]	1	[ 0 ]	intervention 1: This study will compare two treatment arms. Patients will be randomized to either traditional treatment (Ofloxin)or to experimental treatment \[dornase alfa (Pulmozyme®)\]. Each arm will have subjects instilling 5 drops twice daily for 7 days to the affected ear.	intervention 1: dornase alfa (Pulmozyme®)	1	Denver \| Colorado \| United States \| -104.9847 \| 39.73915	41	0	0	0	NCT00419380	1COMPLETED	2011-05-01	2007-01-01	University of Colorado, Denver	7OTHER	false	false	false	null	0	0	0	0	0	0
[ 0 ]	73	NON_RANDOMIZED	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	false	Optimal duration of oral anticoagulant therapy in patients with recurrent episodes of venous thromboembolism (VTE) is a matter of debate and recommendations are based on inadequate evidence. More than 12 months of treatment are currently recommended, and the grade of recommendation is low. The PROLONG study has recent...	null	Venous Thromboembolism	D-dimer Recurrence Venous thromboembolism	null	0	null	null	1	[ 0 ]	intervention 1: tablets, based on INR levels, according to D-dimer levels	intervention 1: Warfarin	1	Varese \| N/A \| Italy \| 8.82511 \| 45.82058	75	0	0	0	NCT00428441	6TERMINATED	2011-05-01	2007-05-01	Università degli Studi dell'Insubria	7OTHER	false	false	false	null	0	0	0	0	0	0
[ 0 ]	30	RANDOMIZED	PARALLEL	0TREATMENT	0NONE	false	0ALL	false	The purpose of this study is to establish an effective method to correct vitamin D deficiency in subjects with cystic fibrosis. The investigators will examine cholecalciferol, ergocalciferol and UV light.	Hypothesis of this study: Our hypothesis is that other methods such as cholecalciferol replacement and/or low dose ultraviolet radiation to the skin may be more effective in raising serum 25-hydroxyvitamin D levels than conventional ergocalciferol therapy. Experimental strategy: We will conduct a prospective randomize...	Cystic Fibrosis		null	3	arm 1: Vitamin D3=cholecalciferol 50,000 IU weekly arm 2: The intervention is an oral tablet of vitamin D2 (ergocaliferol 50,000 IU weekly) for 12 weeks. arm 3: The intervention is the use of a Sunlamp (Sperti) to the skin 5 times a week for 12 weeks	[ 1, 1, 1 ]	3	[ 0, 1, 0 ]	intervention 1: 50,000 IU weekly intervention 2: 5 times a week for 12 weeks intervention 3: 50,000 IU weekly	intervention 1: ergocalciferol (vitamin D2) intervention 2: Sperti Del Sol Lamp intervention 3: Vitamin D3	1	Atlanta \| Georgia \| United States \| -84.38798 \| 33.749	28	0	0	0	NCT00450073	1COMPLETED	2011-05-01	2006-11-01	Atlanta VA Medical Center	1FED	false	false	false	null	0	0	0	0	0	0
[ 2 ]	27	NA	SINGLE_GROUP	1PREVENTION	0NONE	false	0ALL	true	20010133 is an open-label, dose escalation study in pediatric patients with acute leukemias receiving myelotoxic therapy (high dose etoposide, cyclophosphamide and total body irradiation \[TBI\]) followed by hematopoietic stem cell transplant (HSCT). The study will evaluate the safety and pharmacokinetics of palifermin...	null	Leukemia	Oral Mucositis Acute Lymphoblastic Leukemia Acute Myeloid Leukemia Palifermin Kepivance	null	1	arm 1: A 3 dose escalation design. Sucessive cohorts of patient (9 patients per group) will each be administered Palifermin as an IV bolus injection (40, 60 or 80 µg) once daily for 3 consecutive days before the start of conditioning regimen (chemotherapy and total body irradiation) and after HCST (Day -10, -9, -8 and ...	[ 0 ]	3	[ 0, 4, 0 ]	intervention 1: Palifermin will be administered as an IV bolus injection (40, 60 or 80 µg/kg/day)once daily for 3 consecutive days before the start of conditioning regimen and after HCST (Day -10, -9, -8 and Day 0, +1, +2 respectively). intervention 2: None intervention 3: High dose etoposide, Cyclophosphamide	intervention 1: Palifermin intervention 2: Total Body irradiation intervention 3: Chemotherapy	7	Tucson \| Arizona \| United States \| -110.92648 \| 32.22174 Loma Linda \| California \| United States \| -117.26115 \| 34.04835 Los Angeles \| California \| United States \| -118.24368 \| 34.05223 Los Angeles \| California \| United States \| -118.24368 \| 34.05223 Orange \| California \| United States \| -117.85311 \| 33.78779 Chicago \|...	27	0	0	0	NCT00460421	1COMPLETED	2011-05-01	2006-08-01	Swedish Orphan Biovitrum	4INDUSTRY	false	false	false	null	0	0	0	0	0	0
[ 3 ]	24	NA	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	false	This study will examine the effectiveness of S-adenosyl methionine (SAMe) in combination with peginterferon and ribavirin for treating hepatitis C virus. One out of three patients with hepatitis C develops cirrhosis of the liver, which can lead to liver failure or liver cancer. SAMe is a nutritional supplement that is ...	S-adenosyl methionine (SAMe) is a nutritional supplement which is available as an over-the-counter formula. It is a naturally occurring, modified amino acid that is produced in virtually all cells and participates in many biochemical pathways as a major methyl donor and may play a role in intracellular interferon signa...	Chronic Hepatitis C	Hepatitis C Virus Genotype 1 Non-Responders SAMe Natural Killer Cells Interferon Signaling Ribavirin Peginterferon Hemolysis STAT Hepatitis C	null	1	arm 1: None	[ 0 ]	3	[ 0, 0, 0 ]	intervention 1: None intervention 2: None intervention 3: None	intervention 1: Peginterferon alfa-2a intervention 2: Ribavirin intervention 3: S-adenosyl methionine for Chronic Liver Disease	1	Bethesda \| Maryland \| United States \| -77.10026 \| 38.98067	24	0	0	0	NCT00475176	1COMPLETED	2011-05-01	2007-05-01	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	0NIH	false	false	false	null	0	0	0	0	0	0
[ 0 ]	131	RANDOMIZED	PARALLEL	0TREATMENT	2DOUBLE	true	1FEMALE	false	The purpose of this study is to learn if the study drug, doxycycline, can decrease the amount of unplanned vaginal bleeding that women commonly experience when taking combined oral contraception (COC)- pills with estrogen and progestin - in a continuous fashion - no hormone-free week. The study drug, doxycycline, is an...	We intend to conduct a prospective, randomized, placebo controlled, double blind study at Oregon Health and Science University. This study will be conducted over four 28-day cycles (112 days of active COC hormone). All women enrolled in the study will take the same daily low dose COC. This protocol will be divided into...	Contraceptives, Oral	birth control continuous contraception break-through bleeding	null	4	arm 1: None arm 2: None arm 3: None arm 4: None	[ 0, 2, 0, 2 ]	7	[ 0, 0, 0, 0, 0, 0, 0 ]	intervention 1: All women enrolled in the study will take the same daily low dose oral contraceptive (20-mcg EE/90 mcg LNG) dosed in a continuous fashion. intervention 2: 100 mg orally twice a day for five days starting on the first day of breakthrough bleeding. This regimen will be repeated if bleeding persists or rec...	intervention 1: Lybrel intervention 2: Doxycycline intervention 3: Oracea intervention 4: Placebo intervention 5: Doxycycline 100bid x5 days at the time of bleeding intervention 6: Subantimicrobial doxycycline daily intervention 7: placebo daily	2	Honolulu \| Hawaii \| United States \| -157.85833 \| 21.30694 Portland \| Oregon \| United States \| -122.67621 \| 45.52345	130	0	0	0	NCT00480532	1COMPLETED	2011-05-01	2007-05-01	Oregon Health and Science University	7OTHER	false	false	false	null	0	0	0	0	0	0
[ 3 ]	40	RANDOMIZED	PARALLEL	1PREVENTION	4QUADRUPLE	false	0ALL	false	The objective of this 96-week study was to evaluate the safety and antiviral efficacy of emtricitabine/tenofovir disoproxil fumarate (FTC/TDF, coformulated; Truvada®) with or without hepatitis B immunoglobulin (HBIg) in preventing the recurrence of chronic hepatitis B following liver transplantation, in participants wh...	null	Chronic Hepatitis B	Truvada HBIg Chronic Hepatitis B Recurrence Post Orthotopic Liver Transplant	null	2	arm 1: Participants received FTC/TDF+HBIg for up to 24 weeks in the pre-randomization period; those who completed 24 weeks of treatment were then randomized to receive FTC/TDF+HBIg in the randomized period. arm 2: Participants received FTC/TDF+HBIg for up to 24 weeks in the pre-randomization period; those who completed...	[ 0, 0 ]	2	[ 0, 0 ]	intervention 1: Emtricitabine (FTC) 200 mg/tenofovir disoproxil fumarate (TDF) 300 mg was administered as a fixed-dose combination tablet orally once daily. intervention 2: HBIg was administered either intravenously or by intramuscular injection at a dose and frequency as prescribed by the investigative site protocol.	intervention 1: FTC/TDF intervention 2: Hepatitis B Immunoglobulin (HBIg)	7	Los Angeles \| California \| United States \| -118.24368 \| 34.05223 San Francisco \| California \| United States \| -122.41942 \| 37.77493 San Francisco \| California \| United States \| -122.41942 \| 37.77493 Atlanta \| Georgia \| United States \| -84.38798 \| 33.749 Chicago \| Illinois \| United States \| -87.65005 \| 41.85003 New York...	77	0	0	0	NCT00507689	1COMPLETED	2011-05-01	2007-09-01	Gilead Sciences	4INDUSTRY	false	false	false	null	0	0	0	0	0	-0
[ 3 ]	18	NA	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	true	RATIONALE: Drugs used in chemotherapy, such as gemcitabine and doxorubicin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. PURPOSE: This phase II trial is studying h...	null	Head and Neck Cancer	recurrent squamous cell carcinoma of the hypopharynx recurrent squamous cell carcinoma of the larynx recurrent verrucous carcinoma of the larynx recurrent adenoid cystic carcinoma of the oral cavity recurrent basal cell carcinoma of the lip recurrent mucoepidermoid carcinoma of the oral cavity recurrent squamous cell c...	null	1	arm 1: None	[ 0 ]	2	[ 0, 0 ]	intervention 1: given as 25mgm2 IV on days 1 and 8 of each 21-day cycle. intervention 2: given as 100mg/m2 IV over days 1 and 8 of each 21 day cycle	intervention 1: doxorubicin hydrochloride intervention 2: gemcitabine hydrochloride	1	Charleston \| South Carolina \| United States \| -79.93275 \| 32.77632	18	0	0	0	NCT00509665	1COMPLETED	2011-05-01	2005-06-01	Medical University of South Carolina	7OTHER	false	false	false	null	0	0	0	0	0	0
[ 4 ]	687	RANDOMIZED	PARALLEL	0TREATMENT	4QUADRUPLE	false	0ALL	false	The purpose of this study is to assess the ability of eltrombopag to maintain a platelet count sufficient to facilitate initiation of antiviral therapy, to minimise antiviral therapy dose reductions and to avoid permanent discontinuation of antiviral therapy. The clinical benefit of eltrombopag will be measured by the ...	null	Hepatitis C, Chronic	thrombopoietin hepatitis C ribavirin platelets Hepatitis C-related thrombocytopenia peginterferon alfa-2a	null	0	null	null	2	[ 0, 0 ]	intervention 1: 25, 50, 75, 100 mg tablets taken once daily orally intervention 2: matched placebo taken once daily orally	intervention 1: eltrombopag intervention 2: placebo	191	Birmingham \| Alabama \| United States \| -86.80249 \| 33.52066 Tucson \| Arizona \| United States \| -110.92648 \| 32.22174 Little Rock \| Arkansas \| United States \| -92.28959 \| 34.74648 La Jolla \| California \| United States \| -117.2742 \| 32.84727 Los Angeles \| California \| United States \| -118.24368 \| 34.05223 Los Angeles \| C...	1,396	0	0	0	NCT00516321	1COMPLETED	2011-05-01	2007-10-01	GlaxoSmithKline	4INDUSTRY	false	false	false	null	0	0	0	0	0	0
[ 4 ]	459	RANDOMIZED	PARALLEL	0TREATMENT	4QUADRUPLE	false	0ALL	true	This study compares the effectiveness and safety of the combination of anidulafungin and voriconazole compared to that of voriconazole alone (which is generally considered the standard of care) for the treatment of Invasive Aspergillosis.	null	Aspergillosis		null	2	arm 1: Voriconazole monotherapy arm 2: Combination therapy with voriconazole and anidulafungin	[ 1, 0 ]	3	[ 0, 0, 0 ]	intervention 1: First week: Voriconazole 6 mg/kg IV bid for the first 24 hours, followed by 4 mg/kg IV BID plus anidulafungin placebo IV qd. Second week: Voriconazole 4 mg/kg IV bid or 300 mg PO bid plus anidulafungin placebo IV qd. Third and fourth weeks: Voriconazole 4 mg/kg IV bid OR 300 mg PO bid plus anidulafung...	intervention 1: voriconazole intervention 2: anidulafungin intervention 3: voriconazole	107	Birmingham \| Alabama \| United States \| -86.80249 \| 33.52066 Birmingham \| Alabama \| United States \| -86.80249 \| 33.52066 Little Rock \| Arkansas \| United States \| -92.28959 \| 34.74648 La Jolla \| California \| United States \| -117.2742 \| 32.84727 La Jolla \| California \| United States \| -117.2742 \| 32.84727 San Diego \| Cali...	454	0	0	0	NCT00531479	1COMPLETED	2011-05-01	2008-07-01	Pfizer	4INDUSTRY	false	false	false	null	0	0	0	0	0	0
[ 3 ]	106	RANDOMIZED	PARALLEL	0TREATMENT	0NONE	false	0ALL	true	The primary objective of this study is to determine the progression-free survival (PFS) of participants with previously untreated metastatic malignant melanoma when treated with IMC-1121B (ramucirumab) alone or in combination with dacarbazine.	The purpose of this study is to determine the antitumor activity and safety profile of IMC-1121B (ramucirumab) when used alone or in combination with dacarbazine in participants with metastatic melanoma who have not received prior chemotherapy for this disease.	Metastatic Malignant Melanoma	Phase II Melanoma IMC-1121B ImClone	null	2	arm 1: IMC-1121B (ramucirumab) arm 2: IMC-1121B (ramucirumab) + dacarbazine	[ 0, 1 ]	2	[ 2, 0 ]	intervention 1: 10 milligrams/kilogram (mg/kg) intravenously every 3 weeks in the absence of disease progression, unacceptable toxicity, or other withdrawal criteria. intervention 2: 1000 milligrams/square meter (mg/m2) intravenously every 3 weeks in the absence of disease progression, unacceptable toxicity, or other w...	intervention 1: IMC-1121B (ramucirumab) intervention 2: Dacarbazine	17	Decatur \| Alabama \| United States \| -86.98334 \| 34.60593 Scottsdale \| Arizona \| United States \| -111.89903 \| 33.50921 Scottsdale \| Arizona \| United States \| -111.89903 \| 33.50921 Fresno \| California \| United States \| -119.77237 \| 36.74773 San Francisco \| California \| United States \| -122.41942 \| 37.77493 Aurora \| Color...	102	0	0	0	NCT00533702	1COMPLETED	2011-05-01	2007-11-01	Eli Lilly and Company	4INDUSTRY	false	false	false	null	0	0	0	0	0	0
[ 4 ]	1,213	RANDOMIZED	PARALLEL	0TREATMENT	4QUADRUPLE	false	0ALL	true	The Citicoline Brain Injury Treatment (COBRIT) is a randomized, double-blind, placebo controlled, multi-center trial of the effects of 90 days of citicoline on functional outcome in patients with complicated mild, moderate and severe traumatic brain injury.	Traumatic brain injury (TBI) is a major cause of death and disability. In the United States alone approximately 1.4 million sustain a TBI each year, of which 50,000 people die, and over 200,000 are hospitalized. Despite numerous prior clinical trials no standard pharmacotherapy for the treatment of TBI has been establi...	Traumatic Brain Injury	traumatic brain injury cognition behavioral outcome functional outcome treatment early intervention citicoline	null	2	arm 1: Placebo tablets formulated to resemble the citicoline treatment. arm 2: Experimental treatment administered orally or enterally depending upon whether the participant can swallow at 1,000 mg twice a day for 90 days or until the 90-day outcome assessment.	[ 0, 0 ]	2	[ 0, 0 ]	intervention 1: Drug Placebo Inactive twice a day given orally or enterally. The first dose is given within 24 hours of injury and treatment continues until 90 days or until the 90-day outcome assessment. intervention 2: 1000 mg twice a day orally or enterally. The first dose is within 24 hours of injury and treatment ...	intervention 1: Placebo intervention 2: citicoline	8	Birmingham \| Alabama \| United States \| -86.80249 \| 33.52066 Baltimore \| Maryland \| United States \| -76.61219 \| 39.29038 Philadelphia \| Pennsylvania \| United States \| -75.16362 \| 39.95238 Pittsburgh \| Pennsylvania \| United States \| -79.99589 \| 40.44062 Memphis \| Tennessee \| United States \| -90.04898 \| 35.14953 Dallas \| ...	1,213	0	0	0	NCT00545662	6TERMINATED	2011-05-01	2007-07-01	Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	0NIH	false	false	false	null	0	0	0	0	0	0
[ 3 ]	31	NON_RANDOMIZED	SINGLE_GROUP	0TREATMENT	0NONE	false	1FEMALE	false	The purpose of this study is to find out if dasatinib will safely reduce the size or spread of your tumor.	The introduction of biologics with specific molecular targets has initiated a trend toward improved survival in women with metastatic breast cancer. The tyrosine kinase SRC (pp60src) is a member of a family of proteins that contribute to cellular signal transduction activities such as cell growth, differentiation, sur...	Advanced Breast Cancer	Advanced Breast Cancer Breast cancer Dasatinib Inoperable Stage III Breast Cancer Metastatic Breast Cancer Stage IV Breast Cancer	null	1	arm 1: 50- 100 mg PO BID	[ 0 ]	1	[ 0 ]	intervention 1: An initial dose of 50 mg PO BID; following 4 weeks of treatment, dose adjustment will be based on inhibition of phosphorylation of FAK and paxillin per biopsy assessment, as well as toxicity assessment.	intervention 1: Dasatinib	3	West Palm Beach \| Florida \| United States \| -80.05337 \| 26.71534 Charlotte \| North Carolina \| United States \| -80.84313 \| 35.22709 Durham \| North Carolina \| United States \| -78.89862 \| 35.99403	31	0	0	0	NCT00546104	1COMPLETED	2011-05-01	2007-10-01	Duke University	7OTHER	false	false	false	null	0	0	0	0	0	0
[ 3 ]	84	RANDOMIZED	PARALLEL	0TREATMENT	4QUADRUPLE	false	0ALL	false	The primary objective of this study is to evaluate the effectiveness of TCM-700C as an add-on treatment to the combination drug therapy (Peginterferon α-2b plus Ribavirin) for patients with genotype 1 chronic hepatitis C infections. This will be demonstrated by a higher sustained virologic response rate, defined as the...	This was a randomized, double-blind, placebo controlled, parallel-group, Phase 2 study to evaluate the effects of adding a Chinese formulation (TCM-700C) on the standard combination treatment for patients with Genotype 1 hepatitis C infection. Patients were screened within 4 weeks before receive the first study drug do...	Chronic Hepatitis C	add-on treatment botanical drug HCV genotype 1 TCM-700C genotype I	null	2	arm 1: an add-on drug (2 tablets/t.i.d) to conventional treatment(Peginterferon alfa-2a + ribavirin) of Hepatitis C arm 2: placebo add on(2 tablets/t.i.d) to conventional treatment(Peginterferon alfa-2a + ribavirin) of Hepatitis C	[ 0, 2 ]	4	[ 0, 0, 0, 0 ]	intervention 1: An add-on drug to conventional treatment of Hepatitis C intervention 2: conventional treatment of Hepatitis C intervention 3: conventional treatment of Hepatitis C intervention 4: Placebo, without acting ingredient.	intervention 1: TCM-700C intervention 2: Peginterferon alfa-2a intervention 3: Ribavirin intervention 4: Placebo	1	Taoyuan District \| Taiwan \| Taiwan \| 121.3187 \| 24.9896	83	0	0	0	NCT00556504	1COMPLETED	2011-05-01	2007-07-01	TCM Biotech International Corp.	4INDUSTRY	false	false	false	null	0	0	0	0	0	0
[ 5 ]	35	NA	SINGLE_GROUP	0TREATMENT	0NONE	false	1FEMALE	false	The purpose of this study is to use imaging technologies to demonstrate the effects of teriparatide on bone structure following 18 to 24 months of therapy in postmenopausal women with osteoporosis.	As teriparatide is approved for up to 24 months of treatment in the US, patients will be given the option to continue in a 6-month extension phase upon completion of 18 months of teriparatide treatment. This extension will allow for collection of additional bone quality data. In Canada, the use of teriparatide is curre...	Osteoporosis, Postmenopausal	osteoporosis, teriparatide, postmenopausal, MRI, finite element analysis	null	1	arm 1: 20 micrograms (mcg) teriparatide subcutaneous injection per day for 18 months, with possibility to continue for 24 months	[ 0 ]	1	[ 0 ]	intervention 1: 20 mcg teriparatide subcutaneous injection per day for 18 months, with possibility to continue for 24 months	intervention 1: teriparatide	6	Tucson \| Arizona \| United States \| -110.92648 \| 32.22174 Lakewood \| Colorado \| United States \| -105.08137 \| 39.70471 Omaha \| Nebraska \| United States \| -95.94043 \| 41.25626 Albuquerque \| New Mexico \| United States \| -106.65114 \| 35.08449 Pittsburgh \| Pennsylvania \| United States \| -79.99589 \| 40.44062 Vancouver \| Briti...	35	0	0	0	NCT00557310	1COMPLETED	2011-05-01	2007-11-01	Eli Lilly and Company	4INDUSTRY	false	false	false	null	0	0	0	0	0	0
[ 2, 3 ]	56	NA	SINGLE_GROUP	0TREATMENT	0NONE	false	1FEMALE	null	The primary purpose of this study is to identify the maximum tolerated dose (MTD) of both intravenous and oral panobinostat plus trastuzumab. The study will evaluate safety and efficacy of the combination in adult female patients with HER2+ metastatic breast cancer	This phase Ib/IIa study was prematurely terminated due to lack of efficacy noted in 55 patients with HER2-positive MBC who had progressed on or following a trastuzumab-based therapy.	Breast Cancer	Breast Cancer HER2 positive adult-female LBH589 HDAC inhibitor panobinostat	null	1	arm 1: Panobinostat intravenously (i.v.) or orally was given in combination with trastuzumab.	[ 0 ]	2	[ 0, 0 ]	intervention 1: Participants received escalating doses of panobinostat until the maximum tolerated dose (MTD) was reached. The starting dose of panobinostat i.v. was 10mg/m\^2 at days 1 and 8 during a 21-day treatment cycle. The oral panobinostat starting dose was 20 mg twice weekly. intervention 2: Fixed doses of tras...	intervention 1: Panobinostat intervention 2: Trastuzumab	20	Los Angeles \| California \| United States \| -118.24368 \| 34.05223 Aurora \| Colorado \| United States \| -104.83192 \| 39.72943 Norwalk \| Connecticut \| United States \| -73.4079 \| 41.1176 Baltimore \| Maryland \| United States \| -76.61219 \| 39.29038 St Louis \| Missouri \| United States \| -90.19789 \| 38.62727 Columbus \| Ohio \| U...	56	0	0	0	NCT00567879	6TERMINATED	2011-05-01	2008-04-01	Novartis Pharmaceuticals	4INDUSTRY	false	false	false	null	0	0	0	0	0	0
[ 3 ]	30	NA	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	null	This single-arm, open-label study assessed the efficacy and safety of Avastin (bevacizumab) treatment combined with transarterial chemoembolisation (TACE) in patients with localized unresectable liver cancer. Patients were treated with TACE at 8 or 10 week intervals for 4 sessions (continuation depended on investigator...	null	Liver Cancer		null	1	arm 1: Participants received bevacizumab 5 mg/kg intravenously every 2 weeks and within 24-48 hours prior to each transarterial chemoembolization (TACE) until disease progression or unmanageable toxicity. TACE was conducted for 4 sessions at 8-10 week intervals.	[ 0 ]	2	[ 0, 3 ]	intervention 1: Bevacizumab was supplied as a sterile liquid in single-use vials. intervention 2: TACE was conducted by the transfemoral artery approach with selective cannulation of the artery supplying the tumor. Cisplatin mixed with Lipiodol in a 1 mg:1 mL ratio was infused intra-arterially up to a maximum dose of 3...	intervention 1: Bevacizumab intervention 2: Transarterial chemoembolisation (TACE)	3	Hong Kong \| N/A \| Hong Kong \| 114.17469 \| 22.27832 Hong Kong \| N/A \| Hong Kong \| 114.17469 \| 22.27832 Hong Kong \| N/A \| Hong Kong \| 114.17469 \| 22.27832	30	0	0	0	NCT00576199	1COMPLETED	2011-05-01	2008-02-01	Hoffmann-La Roche	4INDUSTRY	false	false	false	null	0	0	0	0	0	0
[ 0 ]	174	RANDOMIZED	PARALLEL	0TREATMENT	0NONE	true	1FEMALE	true	This is a randomized controlled trial comparing weekly intramuscular injection of 17 alpha hydroxylprogesterone caproate with daily vaginal progesterone in women with singleton pregnancies and history of prior spontaneous preterm birth in terms of maternal, fetal and neonatal outcomes. Our aim is to assess the effects...	This study is intended as a randomized controlled trial. Women with singleton pregnancies between 16 and 20 weeks 6 day will be randomized to one of two treatment groups. Those randomized to weekly intramuscular progesterone will receive 250 mg of 17 alpha hydroxyprogesterone caproate every week in the clinic between ...	Infant, Premature Premature Birth	Pre Term Pre Term Birth Premature Birth Premature baby High risk pregnancy Progesterone IM Progesterone Vaginal Progesterone	null	2	arm 1: Intramuscular Progesterone arm 2: Vaginal Progesterone	[ 1, 0 ]	2	[ 0, 0 ]	intervention 1: Intramuscular Progestone: 17 alpha hydroxyprogesterone caproate: weekly 1 cc injections containing 250 mg of 17P intervention 2: Vaginal Progesterone: 100 mg vaginal suppository daily	intervention 1: Intramuscular Progesterone intervention 2: Vaginal Progesterone	1	Oklahoma City \| Oklahoma \| United States \| -97.51643 \| 35.46756	145	0	0	0	NCT00579553	1COMPLETED	2011-05-01	2006-10-01	University of Oklahoma	7OTHER	false	false	false	null	0	0	0	0	0	0
[ 0 ]	76	RANDOMIZED	PARALLEL	2DIAGNOSTIC	3TRIPLE	true	1FEMALE	false	This study is been designed to answer the question of whether local anesthesia (1% lidocaine) decreases the perception of pain associated with amniocentesis in a randomized double blind placebo controlled manner. Our objective is to determine the effect of local anesthesia on the maternal pain perception from an amnioc...	Women meeting criteria for project and agreeing to treatment will be randomized into either the 1% Lidocaine or placebo(normal saline) group. The initial injection of either 1% lidocaine or placebo (normal saline) will be administered 2 minutes prior to the amniocentesis procedure. 2cc of 1% lidocaine or placebo (norma...	Pregnancy	Amniocentesis Genetic amniocentesis Fetal lung maturity Pain control Pregnancy High risk pregnancy	null	2	arm 1: Local anesthesia group. 2cc of 1% lidocaine with epinephrine administered 2 minutes before amniocentesis, using a 21 gauge needle initially as an intradermal wheal followed by a deeper infiltration of 2cc of 1% lidocaine to the depth of the peritoneum. arm 2: Placebo normal saline group. 2cc of normal saline epi...	[ 0, 2 ]	2	[ 0, 0 ]	intervention 1: Local anesthesia: 2 cc of 1% Lidocaine intervention 2: Placebo Group: 2cc Normal Saline	intervention 1: Local Anesthesia intervention 2: Placebo Group	1	Oklahoma City \| Oklahoma \| United States \| -97.51643 \| 35.46756	76	0	0	0	NCT00583011	1COMPLETED	2011-05-01	2007-10-01	University of Oklahoma	7OTHER	false	false	false	null	0	0	0	0	0	0
[ 3 ]	129	NA	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	null	This is a phase II, single-center study to evaluate the efficacy of a novel cytoreductive regimen followed by CD34+E- selected T cell depleted allogeneic stem cell (or soybean agglutinated and E-rosetted BM) transplant as treatment for patients with acute and chronic leukemias, lymphoma and myelodysplstic syndrome/PNH....	The purpose of this study is: (1) to try to kill any cancer or precancer cells that are in your body, and to reduce the side effects of a transplant, which we have seen in our previous studies, (2) to see if this treatment with a new recipe of radiation and chemotherapy can suppress your immune system enough for the st...	Allogeneic Stem Cell Transplant Leukemia Non-Hodgkins Lymphoblastic Lymphoma Myelodysplastic Syndrome Paroxysmal Nocturnal Hemoglobinuria (PNH)	leukemia non-Hodgkins lymphoblastic lymphoma myelodysplastic syndrome paroxysmal nocturnal hemoglobinuria (PNH) cytoreductive regimen allogeneic stem cell transplant	null	1	arm 1: None	[ 0 ]	1	[ 0 ]	intervention 1: Myeloablative and will consist of hyperfractionated TBI - 1375 cGy administered in 11 doses of 125 cGy each over a total of four days, with three doses on three days and two doses on the last day, fludarabine 25 mg/m2 IV x 5 days, and thiotepa 5mg/kg IV x 2 days. Recipients of HLA identical related tran...	intervention 1: cytoreductive regimen followed by a CD34+E- selected allogeneic stem cell transplant	1	New York \| New York \| United States \| -74.00597 \| 40.71427	129	0	0	0	NCT00587054	1COMPLETED	2011-05-01	2001-06-01	Memorial Sloan Kettering Cancer Center	7OTHER	false	false	false	null	0	0	0	0	0	0
[ 3 ]	23	RANDOMIZED	PARALLEL	0TREATMENT	0NONE	false	0ALL	true	The objective of the study is to compare two different doses of Peg-INF-α-2A (90 or 180 ug/wk) for their ability to maintain viral control when initiated 5 weeks before ART (antiretroviral therapy) interruption in HIV positive, ART-suppressed subjects (viral load \<50 copies/ml) as determined by observing the percentag...	The high toxicity of current Anti-Retroviral Therapy (ART) regimens has driven a number of studies investigating therapeutic approaches aimed at reducing drug exposure while maintaining the beneficial effects of immune reconstitution. Preliminary observations in HCV/HIV co-infected individuals already support an antivi...	HIV Infections	HIV HIV-1 Pegasys Peg-IFN-Alpha-2A Viral Suppression ART cessation Immune function Innate Immunity Toxicity Immune-based therapy Treatment interruption	null	2	arm 1: ART replacement treatment with Pegylated Interferon-alpha 2a, 180 mcg/week sc arm 2: ART replacement treatment with Pegylated Interferon-alpha 2a, 90 mcg/week sc	[ 1, 1 ]	2	[ 0, 0 ]	intervention 1: Pegylated Interferon-alpha 2a, 90 mcg/week sc for 24 weeks, 5 weeks in combination with ART, then 7 weeks without ART to primary endpoint (VL \< 400 c/ml at 12 weeks) and further 12 weeks without ART (24 weeks) to secondary endpoints intervention 2: Pegylated Interferon-alpha 2a, 90 mcg/week sc for 24 w...	intervention 1: Pegylated Interferon-alpha 2a, 180 mcg/week sc intervention 2: Pegylated Interferon-alpha 2a, 90 mcg/week sc	5	Philadelphia \| Pennsylvania \| United States \| -75.16362 \| 39.95238 Philadelphia \| Pennsylvania \| United States \| -75.16362 \| 39.95238 Philadelphia \| Pennsylvania \| United States \| -75.16362 \| 39.95238 Philadelphia \| Pennsylvania \| United States \| -75.16362 \| 39.95238 Philadelphia \| Pennsylvania \| United States \| -75.16...	23	0	0	0	NCT00594880	1COMPLETED	2011-05-01	2008-01-01	The Wistar Institute	7OTHER	false	false	false	null	0	0	0	0	0	0
[ 4 ]	288	RANDOMIZED	PARALLEL	0TREATMENT	2DOUBLE	false	0ALL	false	The purpose of this study is to demonstrate that the new modified oral extended-release Pentasa® 500mg tablet is at least as efficacious as the currently marketed Pentasa® 500mg tablet in active mild to moderate Ulcerative Colitis (UC) and also in maintenance of quiescent disease.	A multi-centre, randomized, double-blind, non-inferiority trial comparing the efficacy and safety of a new modified oral extended release Pentasa® (mesalamine) 500 mg tablet to the currently marketed Pentasa® (mesalamine) 500 mg tablet in subjects with active mild to moderate ulcerative colitis treated with 4 g/day for...	Active Ulcerative Colitis Remission of Ulcerative Colitis	Ulcerative Colitis 5-Aminosalicylate	null	2	arm 1: 5-ASA (5-Aminosalicylate) arm 2: 5-ASA (5-Aminosalicylate)	[ 0, 1 ]	2	[ 0, 0 ]	intervention 1: 500 mg tablet (modified extended release) intervention 2: 500 mg tablet	intervention 1: 5-ASA (5-Aminosalicylate) intervention 2: 5-ASA (5-Aminosalicylate)	27	Calgary \| Alberta \| Canada \| -114.08529 \| 51.05011 Edmonton \| Alberta \| Canada \| -113.46871 \| 53.55014 Brandon \| Manitoba \| Canada \| -99.95306 \| 49.84692 Saint John \| New Brunswick \| Canada \| -66.05616 \| 45.27076 Barrie \| Ontario \| Canada \| -79.66634 \| 44.40011 Greater Sudbury \| Ontario \| Canada \| -80.99001 \| 46.49 Gue...	287	0	0	0	NCT00603733	1COMPLETED	2011-05-01	2007-10-01	Ferring Pharmaceuticals	4INDUSTRY	false	false	false	null	0	0	0	0	0	0
[ 5 ]	4	RANDOMIZED	PARALLEL	1PREVENTION	2DOUBLE	true	0ALL	true	The combination of high blood pressure and having central obesity is an increasing important factor for heart disease in men and women. It can also lead to the early development of hardening of the arteries and increased risk of a stroke. This study will analyze patients' genetic make up to identify who may be at great...	Obesity is an increasingly important risk factor for cardiovascular disease in men and women and is associated with the premature development of atherosclerosis, and increased risk of stroke. A classical perspective of cardiovascular risk does not adequately explain all of the cardiovascular events associated with obes...	Metabolic Syndrome X	Fibrolytic Dysfunction Obesity PAI-1	null	2	arm 1: Eplerenone (study drug) arm 2: Ramipril	[ 1, 1 ]	2	[ 0, 0 ]	intervention 1: 5 mg x 1 week followed by 10 mg x 9 weeks. intervention 2: Ramipril 5mg qd x 1 week f/b Ramipril qd x 9 weeks.	intervention 1: Eplerenone intervention 2: Ramipril	1	Nashville \| Tennessee \| United States \| -86.78444 \| 36.16589	4	0	0	0	NCT00608465	6TERMINATED	2011-05-01	2006-05-01	Vanderbilt University	7OTHER	false	false	false	null	0	0	0	0	0	0
[ 0 ]	6	NON_RANDOMIZED	PARALLEL	0TREATMENT	0NONE	false	0ALL	true	RATIONALE: Giving chemotherapy and total-body irradiation before a donor umbilical cord blood transplant helps stop the growth of cancer and abnormal cells and helps stop the patient's immune system from rejecting the donor's stem cells. When the healthy stem cells from a donor are infused into the patient they may hel...	OBJECTIVES: Primary * To determine the safety (as assessed by the day 100 non-relapse mortality) and feasibility of single or double umbilical cord stem cell transplantation in patients with hematological malignancies receiving graft-versus-host disease (GVHD) prophylaxis comprising tacrolimus and mycophenolate mofet...	Graft Versus Host Disease Leukemia Lymphoma Multiple Myeloma and Plasma Cell Neoplasm Myelodysplastic Syndromes	graft versus host disease accelerated phase chronic myelogenous leukemia adult acute lymphoblastic leukemia in remission adult acute myeloid leukemia in remission adult acute myeloid leukemia with 11q23 (MLL) abnormalities adult acute myeloid leukemia with inv(16)(p13;q22) adult acute myeloid leukemia with t(15;17)(q22...	null	3	arm 1: Patients undergo total-body irradiation on days -7 to -4, and receive cyclophosphamide IV over 1 hour on days -3 and -2, methylprednisolone IV twice daily on days -3 to -1, and anti-thymocyte globulin IV over 4 hours on days -3 to -1. arm 2: Patients receive fludarabine phosphate IV over 30 minutes on days -6 to...	[ 0, 0, 0 ]	5	[ 2, 0, 0, 0, 4 ]	intervention 1: Given IV intervention 2: Given IV intervention 3: Given IV intervention 4: Given IV intervention 5: Given daily for 1-4 days	intervention 1: anti-thymocyte globulin intervention 2: cyclophosphamide intervention 3: fludarabine phosphate intervention 4: methylprednisolone intervention 5: total-body irradiation	4	Nashville \| Tennessee \| United States \| -86.78444 \| 36.16589 Nashville \| Tennessee \| United States \| -86.78444 \| 36.16589 Nashville \| Tennessee \| United States \| -86.78444 \| 36.16589 Nashville \| Tennessee \| United States \| -86.78444 \| 36.16589	6	0	0	0	NCT00608517	6TERMINATED	2011-05-01	2005-09-01	Vanderbilt-Ingram Cancer Center	7OTHER	false	false	false	null	0	0	0	0	0	0
[ 0 ]	43	RANDOMIZED	FACTORIAL	0TREATMENT	3TRIPLE	false	0ALL	false	Dexamethasone is a commonly used steroid. This medication has been used for many years by physicians for many different indications. Recent articles, multiple case reports, and experience at this institution have indicated that dexamethasone successfully prolongs the effective duration of local anesthetics for regional...	null	Total Knee Arthroplasty	Total Knee Arthroplasty. Sciatic nerve Blocks. Dexamethasone.	null	3	arm 1: This is the control arm and subjects in Group A will have sciatic nerve block with 20ml of 0.2% Ropivacaine + 2ml IV of normal saline. arm 2: Subjects in Group B will have sciatic nerve block with 20ml of 0.2% Ropivacaine + 8mg Dexamethasone + 2ml IV of normal saline. arm 3: Subjects in Group C will have sciatic...	[ 5, 0, 1 ]	4	[ 0, 0, 0, 0 ]	intervention 1: 20 ml of 0.2% ropivacaine injected locally as regional anesthesia given once. intervention 2: 8mg Dexamethasone injected locally along with ropivacaine for regional anesthesia given once. intervention 3: 2ml(8mg)Dexamethasone given once intravenously. intervention 4: 2ml of normal saline given once intr...	intervention 1: Ropivacaine intervention 2: Dexamethasone intervention 3: Dexamethasone intervention 4: Normal Saline	1	Loma Linda \| California \| United States \| -117.26115 \| 34.04835	0	0	0	0	NCT00616603	6TERMINATED	2011-05-01	2007-08-01	Loma Linda University	7OTHER	false	false	false	null	0	0	0	0	0	0
[ 3, 4 ]	447	RANDOMIZED	PARALLEL	0TREATMENT	4QUADRUPLE	false	0ALL	true	This study aims to examine the effect of nebulized 3% hypertonic saline in the treatment of viral bronchiolitis. The investigators hypothesize that nebulized 3% saline will decrease rate of hospital admission, decrease clinical severity scores, and decrease length of stay.	Bronchiolitis is the most common viral respiratory infection in young children and infants. It is responsible for hundreds of thousands of outpatient visits and hospitalizations every year. Hypertonic saline may decrease swelling in the lung tissue, improve the patient's ability to clear secretions, and decrease nasal ...	Bronchiolitis	bronchiolitis hypertonic saline	null	2	arm 1: 3% NaCl, 4 mL inhalation, up to 3 inhalations every 20 minutes in the ED, and Q8H in the inpatient setting. arm 2: 0.9% NaCl, 4 mL inhalation, up to 3 inhalations every 20 minutes in the ED, and Q8H in the inpatient setting.	[ 0, 2 ]	2	[ 0, 0 ]	intervention 1: 4 ml inhaled q8h intervention 2: normal saline	intervention 1: Nebulized 3% saline intervention 2: Nebulized 0.9% saline	2	Los Angeles \| California \| United States \| -118.24368 \| 34.05223 Oakland \| California \| United States \| -122.2708 \| 37.80437	447	0	0	0	NCT00619918	1COMPLETED	2011-05-01	2008-02-01	Children's Hospital Los Angeles	7OTHER	false	false	false	null	0	0	0	0	0	0
[ 3 ]	45	NA	SINGLE_GROUP	9OTHER	0NONE	false	0ALL	false	To determine the pharmacokinetic profile of IV (intravenous) and PO (oral) formulations of linezolid among children with cystic fibrosis and establish a dose regimen that will be safe and effective.	Patients with cystic fibrosis who have pulmonary exacerbations associated with the isolation of Methicillin-resistant Staphylococcus aureus (MRSA) in their sputum will be identified by their primary physicians and by laboratory record review. If they meet the inclusion criteria, they will be invited to participate in t...	Cystic Fibrosis	Pharmacokinetic	null	1	arm 1: None	[ 0 ]	1	[ 0 ]	intervention 1: Pharmacokinetics daily dose of linezolid at 15 mg/kg/dose Intravenously (IV) based on subject's weight at study entry, over half an hour period, every 8 hours for a minimum of 7 days to a maximum of 28 days total. The primary doctor may change the route of administration of linezolid from IV to oral (b...	intervention 1: Linezolid	1	Dallas \| Texas \| United States \| -96.80667 \| 32.78306	0	0	0	0	NCT00625703	1COMPLETED	2011-05-01	2010-12-01	University of Texas Southwestern Medical Center	7OTHER	false	false	false	null	0	0	0	0	0	0
[ 4 ]	2,577	RANDOMIZED	PARALLEL	0TREATMENT	3TRIPLE	false	2MALE	true	Enthuse M0 is a large phase III clinical trial studying the efficacy of ZD4054 (Zibotentan) in hormone resistant prostate cancer (HRPC). This clinical trial will test if the Endothelin A Receptor Antagonist ZD4054 (Zibotentan) can improve progression-free survival and overall survival against a background of existing ...	null	Prostate Cancer	Hormone Resistant Prostate Cancer Endothelin A Receptor Antagonist Endothelin A Endothelin A antagonist	null	2	arm 1: Matching Placebo arm 2: ZD4054 (Zibotentan)	[ 2, 0 ]	2	[ 0, 0 ]	intervention 1: 10 mg once daily oral dose intervention 2: Matching Plcebo oral tablet once daily	intervention 1: ZD4054 intervention 2: Palcebo	322	Tucson \| Arizona \| United States \| -110.92648 \| 32.22174 Greenbrae \| California \| United States \| -122.5247 \| 37.94854 Los Angeles \| California \| United States \| -118.24368 \| 34.05223 San Diego \| California \| United States \| -117.16472 \| 32.71571 San Francisco \| California \| United States \| -122.41942 \| 37.77493 Denver...	1,415	0	0	0	NCT00626548	6TERMINATED	2011-05-01	2008-01-01	AstraZeneca	4INDUSTRY	false	false	false	null	0	0	0	0	0	0
[ 0 ]	32	RANDOMIZED	PARALLEL	0TREATMENT	3TRIPLE	false	1FEMALE	false	To determine if augmentation with the oral-contraceptive pill containing drospirenone and ethinyl estradiol is more effective than placebo in the treatment of premenstrual breakthrough of depression.	null	Premenstrual Syndrome Depression	Women PMS Depression	null	2	arm 1: None arm 2: None	[ 0, 2 ]	2	[ 0, 0 ]	intervention 1: Once daily by mouth intervention 2: Once daily by mouth	intervention 1: Drospirenone and ethinyl estradiol intervention 2: Placebo	1	Boston \| Massachusetts \| United States \| -71.05977 \| 42.35843	32	0	0	0	NCT00633360	1COMPLETED	2011-05-01	2008-02-01	Massachusetts General Hospital	7OTHER	false	false	false	null	0	0	0	0	0	0
[ 4 ]	63	NON_RANDOMIZED	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	null	To evaluate the safety, tolerability, and efficacy of caspofungin for the treatment of esophageal candidiasis and invasive candidiasis to support the registration of caspofungin for these indications in China.	null	Fungal Infection		null	1	arm 1: None	[ 0 ]	1	[ 0 ]	intervention 1: Intravenous (IV) caspofungin acetate 50 mg/day. Participants with esophageal candidiasis will be treated for at least 7 days and for at least 72 hours after symptoms resolve for a maximum of 28 days; participants with invasive candidiasis will have a 70 mg loading dose on study day 1 and will be treated...	intervention 1: caspofungin acetate	0	null	63	0	0	0	NCT00635648	1COMPLETED	2011-05-01	2008-01-01	Merck Sharp & Dohme LLC	4INDUSTRY	false	false	false	null	0	0	0	0	0	0
[ 3, 4 ]	1,579	RANDOMIZED	PARALLEL	0TREATMENT	2DOUBLE	true	0ALL	true	Evaluate the safety, PK and efficacy comparing Pagibaximab Injection to placebo in preventing staphylococcal sepsis in very low birth weight infants. 1550 infants will be enrolled prior to 48 hours of life and will be randomized 1:1 to receive active drug or placebo on study days 0, 1, 2, 9, 16, and 23.	Phase 2b/3, randomized, double-blind, multicenter, placebo-controlled study evaluating the safety, efficacy and pharmacokinetics (PK) of pagibaximab (100 mg/kg/dose) in comparison to placebo for the prevention of staphylococcal sepsis in VLBW infants (600 -1200 grams). Subjects monitored for treatment related adverse e...	Staphylococcal Sepsis	Staphylococcal Coagulase Negative Staphylococcus Monoclonal antibodies Very Low Birth Weight Infants Prophylaxis	null	2	arm 1: Phosphate Buffered Saline arm 2: Pagibaximab at 100 mg/kg intravenously at Days 0, 1, 2, 9, 16 and 23.	[ 2, 0 ]	2	[ 0, 0 ]	intervention 1: Phosphate Buffered Saline on Days 0, 1, 2, 9, 16 and 23. intervention 2: Pagibaximab 100 mg/kg dosed on Days 0, 1, 2, 9, 16 and 23	intervention 1: Placebo intervention 2: Pagibaximab 50 mg/mL	1	Gaithersburg \| Maryland \| United States \| -77.20137 \| 39.14344	1,562	0	0	0	NCT00646399	1COMPLETED	2011-05-01	2009-03-01	Biosynexus Incorporated	4INDUSTRY	false	false	false	null	0	0	0	0	0	0
[ 5 ]	23	NA	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	false	The purpose of this study is to learn more about symptoms and gastrointestinal lesions associated with taking myfortic® by switching patients to a delayed release formulation that is developed to alleviate GI symptoms. A comparison of the frequency and severity of GI symptoms observed in patients treated with MMF (cell...	Myfortic® recently introduced to the market has shown to be similar to MMF in how effectively it works and how well it is tolerated. Both drugs have the same active ingredient, but they are different in the way that they deliver them to the body. Myfortic® is an advanced, enteric coated formulation of mycophenolate sod...	Gastrointestinal Lesions Signs and Symptoms, Digestive	Renal transplant recipients Gastrointestinal findings in small bowel capsule endoscopy Mycophenolic acid Mycophenolate Mofetil Mycophenolate Sodium	null	1	arm 1: This was a four-week study designed to investigate GI mucosal lesions by SBCE in kidney transplant recipients who were using MMF, and to examine the changes in clinical symptoms and intestinal mucosa lesions 30 days after switching over from MMF to EC-MPS. The patient was switched from MMF to EC-MPS (Myfortic) o...	[ 5 ]	2	[ 3, 0 ]	intervention 1: SBCE will be performed at Day 2 and Day 30. intervention 2: switching from mycophenolate mofetil to mycophenolic acid on equimolar basis	intervention 1: Small bowel capsule endoscopy (SBCE) intervention 2: myfortic	1	Los Angeles \| California \| United States \| -118.24368 \| 34.05223	23	0	0	0	NCT00652834	1COMPLETED	2011-05-01	2009-04-01	University of California, Los Angeles	7OTHER	false	false	false	null	0	0	0	0	0	0
[ 3 ]	65	RANDOMIZED	FACTORIAL	0TREATMENT	4QUADRUPLE	false	0ALL	true	The principal aim of this exploratory study is to examine whether the addition of aripiprazole to naltrexone will enhance efficacy over naltrexone alone in a 16-week randomized, placebo-controlled clinical trial, in which all subjects will be provided medical management as delivered in the COMBINE Study (Anton et al, 2...	null	Alcohol Dependence	Alcohol Dependence Alcoholism Naltrexone Aripiprazole Substance Abuse	null	3	arm 1: None arm 2: Naltrexone arm 3: Naltrexone + Aripiprazole	[ 2, 1, 1 ]	3	[ 0, 0, 0 ]	intervention 1: placebo intervention 2: Naltrexone (25mg or 50 mg per titration schedule) intervention 3: Naltrexone + Aripiprazole (5mg - 15mg per titration schedule)	intervention 1: Placebo intervention 2: Naltrexone intervention 3: Naltrexone + Aripiprazole	1	Charleston \| South Carolina \| United States \| -79.93275 \| 32.77632	65	0	0	0	NCT00667875	1COMPLETED	2011-05-01	2008-04-01	Medical University of South Carolina	7OTHER	false	false	false	null	0	0	0	0	0	0
[ 5 ]	6	NA	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	false	Once daily antiretroviral therapy with Viread (tenofovir DF, 300mg) plus Kaletra (LPV/r, 800mg/200mg) will be effective in suppressing and maintaining suppression of HIV RNA to \<50 copies/ml in antiretroviral naïve patients through 48 weeks of therapy.	This study is a phase IV prospective, open-label, controlled treatment protocol consisting of once daily Kaletra dosed at 800mg lopinavir with 200mg ritonavir in four combination tablets plus Viread dosed as 300 mg tenofovir DF. This will be a single site, multi-investigator, study for 48 weeks. Consecutive eligible pa...	HIV Infections	HIV AIDS HIV/AIDS Treatment Naive	null	1	arm 1: Patients taking 4 (four) lopinavir/ritonavir (200mg/50mg tablets) and 1 (one) tenofovir (300mg tablet) every 24 (twenty four) hours.	[ 0 ]	1	[ 0 ]	intervention 1: Four tablets of lopinavir/ritonavir and one tablet of tenofovir given once daily	intervention 1: Once daily	1	Tulsa \| Oklahoma \| United States \| -95.99277 \| 36.15398	15	0	0	0	NCT00679926	6TERMINATED	2011-05-01	2008-05-01	Oklahoma State University Center for Health Sciences	7OTHER	false	false	false	null	0	0	0	0	0	0

Subsets and Splits

No community queries yet

The top public SQL queries from the community will appear here once available.